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ABBREVATIONS AND DEFINITIONS 
List of abbreviations 
CI  Confidence interval 
CBT  Cognitive behaviour therapy 
CNS  Central nervous system 
ENS  Enteric nervous System 
EPQ-10 Eysenck personality questionnaire, 10 items version  
FGID  Functional gastrointestinal disorders  
FBD  Functional bowel disorders 
FD  Functional dyspepsia 
GERD  Gastroesophageal reflux disease 
GP  General practitioner 
IBD  Inflammatory bowel disorder 
IBS  Irritable bowel syndrome 
NHSS  National health screening service 
OR  Odds ratio 
SHC   Subjective health complaints 
SCL-10 Symptom check list-10 items version 
SF-12  Short form-12 
UK  United Kingdom 
SD  Standard deviation 
US  United States of America 
Terms and definitions  
In the appendix, I comment on the following perhaps confusing terms and definitions: 
9 IBS; Disease, disorder or illness? Functional or organic? 
9 Aetiology, pathogenesis, causes and mechanisms 
9 Comorbidity of IBS, subjective health complaints, somatisation or medically unexplained 
physical symptoms (MUPS)? 
9 Consultation behaviour in IBS: Subjects with IBS, consulters/ non-consulters or 
patients/ non-patients? 
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GENERAL INTRODUCTION 
Abdominal complaints, organic diseases and functional gastrointestinal disorders  
Symptoms from the gastrointestinal tract occur so frequently in humans that it is probably 
abnormal not to experience symptoms such as heartburn, abdominal pain/ discomfort, bloating, 
constipation or diarrhoea.1 Such symptoms do not necessarily represent diagnosable disorders or 
diseases, nor result in contact with health care. Yet, abdominal complaints constitute a frequent 
reason for consultation both in general practice and in secondary health care.2 Doctors need to 
correctly diagnose disorders and diseases to provide effective treatment. A correct distinction 
between organic diseases (within or outside the gastrointestinal tract) and functional 
gastrointestinal disorders is of particular relevance in this context. 
 Organic gastrointestinal diseases such as gastroesophageal reflux disease (GERD), peptic 
ulcer disease, inflammatory bowel disorder, celiac disease, hepatobiliary disease and 
gastrointestinal cancer are characterised by structural lesions or biochemical abnormalities, which 
can be identified by additional investigations.  
 Symptoms of functional gastrointestinal disorders (FGID) are reported by 60%-70% of 
adults in the community and constitute about half of diagnoses for abdominal complaints in 
general practice and gastroenterology units.1-4 FGID are defined as variable combinations of 
chronic or recurrent gastrointestinal symptoms attributed to all levels of the gastrointestinal tract 
that have no structural or biochemical explanation.5To date, 20 different diagnostic entities have 
been defined, from the oesophagus to the anus. Irritable bowel syndrome (IBS) and functional 
dyspepsia (FD) are the most frequent FGID and have been the most studied. With regard to IBS, 
there is an abundant literature on patients with IBS referred to specialists but little is known 
about the nature of IBS in general practice, where most patients are cared for. Knowledge about 
the nature of IBS in community subjects and their differences from those who see doctors could 
increase our understanding of this frequent and for some very troubling disorder. The objective 
of this thesis was therefore to study the prevalence, diagnosis and characteristics of IBS in general 
practice and in the general population of Norway. Throughout the work with this thesis I have 
become increasingly interested in the comorbidity of IBS, which is reflected in paper III and IV.  
What is IBS, a historical view and the road to Rome 
IBS is a chronic disorder, characterised by abdominal pain/ discomfort associated with 
defecation or a change in bowel habit, and with features of disordered defecation (Rome II).6
Bloating and abdominal distension are typical, together with other supportive symptoms which 
cumulatively support the diagnosis of IBS (figure 1). Constipation and diarrhoea are the main 
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forms of bowel disturbances, and the supportive symptoms allow a division into constipation 
predominant IBS, diarrhoea predominant IBS and alternating IBS. The onset of IBS may occur 
in childhood or during all stages of adulthood and most will experience a waxing and waning 
course with combinations of altered bowel habits and great turnover of symptoms.7 On long 
term follow up, most patients with a diagnosis of IBS still have bowel symptoms but there is no 
increased risk of organic complications or mortality.8;9
Described by Powell in a scientific paper already in 1818, IBS is not a disorder of modern 
living. Over 150 years ago, the heterogeneity of symptoms puzzled Cumming who wrote “the 
bowels are at one time constipated, another lax, in the same person…How the disease has two 
such different symptoms I do not profess to explain”.10 However, the first systematic look at the 
syndrome was the classic 1962 paper by Chaudhary and Truelove entitled “the Irritable colon”.11
We now know that more than the colon is involved, hence the modern label the Irritable bowel 
syndrome, abbreviated IBS. Although IBS is an accepted label in both epidemiological and 
clinical research, we know little about how IBS is perceived or labelled by its sufferers or by 
health care providers. In Europe, only a minority of patients are formally diagnosed with IBS or 
its synonyms.12 In Norway, other labels such as irritable colon, dyspepsia, gastritis (magekatarr) 
nervous stomach (nervøs mage), or “abdominal complaints” (mageplager) are probably just as 
frequently used by patients and doctors. Some authors argue that IBS must be considered a 
disease, at least when symptoms become persistent and severe.13
Irritable bowel syndrome was deemed a diagnosis of exclusion until the Manning criteria 
were presented in 1978.14 This first set of symptom based diagnostic criteria for IBS, identifying 
six symptoms able to discriminate IBS from organic disease, soon became used in 
epidemiological and clinical studies. New criteria were developed through the Rome working 
teams, resulting in the Rome I criteria in 1992 and the Rome II criteria in 1999 (figure 1).6 The 
work of the Rome committee, based on available evidence from research and a consensus expert 
approach, has resulted in a standardisation of entry criteria into clinical studies, allowing 
investigators to compare their results with greater confidence. The definitions used in this thesis 
are based on the Rome II consensus. However, the Rome II criteria are to be followed by the 
Rome III criteria during 2006. 
- 8 - 
Figure 1: Rome II diagnostic criteria* for IBS 
At least 12 weeks, which need not be consecutive, in the preceding 12  months of 
abdominal discomfort or pain that has two out of three features: 
x Relieved with defecation; and/or 
x Onset associated with a change in frequency of stool; and/or 
x Onset associated with a change in form (appearance) of stool. 
Symptoms that cumulatively support the diagnosis of IBS  
x Abnormal stool frequency (for research purposes “abnormal” may be defined as 
greater than 3 movements per day and less than 3 bowel movements per week); 
x Abnormal stool form (lumpy/hard or loose/watery stool); 
x Abnormal stool passage (straining, urgency, or feeling of incomplete evacuation); 
x Passage of mucus 
x Bloating or feeling of abdominal distension 
* In the absence of structural or metabolic abnormalities to explain the symptoms 
Causes and mechanisms in IBS 
Despite extensive research, little is known about the pathogenesis of IBS and even less of its 
cause. Over the past thirty years, there has been a pendular movement from considering IBS a 
psychosomatic condition to a “little understood organic disease”.13;15 Although this 
“organification” of IBS is welcomed by some, IBS is by most considered a  “a brain-gut 
disorder”: The typical cluster of symptoms results from a complex interplay of peripheral, central 
and environmental factors interacting on the brain-gut axis, and they do so to different degrees 
across individuals and even for the same individual over time.16 This interplay involves both 
motor and sensory dysfunction and is consistent with an up-regulation in neural processing 
between the gut and the brain.17 The “brain-gut” theory embraces psychological as well as 
physical factors and respects the indivisibility of mind and body. It fits comfortably with the 
biopsychosocial model of disease which is frequently used to conceptualize the pathogenesis of 
IBS.18-20
 Biological factors likely to play a role in IBS include visceral hypersensitivity, infection, 
inflammation, disturbed motility, abnormal gas production or transit, altered intestinal secretion, 
abnormal gut flora and food intolerance/ allergy. Visceral hypersensitivity, defined as increased 
sensitivity to gut stimuli, is the biological factor most strongly associated with symptoms of IBS. 
Rectal hypersensitivity has been proposed to be a useful marker for IBS, but not all subjects with 
IBS exhibit sensory thresholds outside the normal range.21-23 Furthermore, processing of visceral 
pain is complex and involves both the Enteric nervous system (ENS) and the Central nervous 
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system (CNS).24 Emotional states may have important influences on sensitivity, as demonstrated 
by novel functional brain imaging techniques (functional MRI or PET-scan). For instance, fear of 
painful stimuli (anticipation) increases visceral hypersensitivity.25Altered CNS processing of 
visceral sensations, particularly pain, is demonstrated in patients with IBS. In particular, increased 
activity of the limbic system and impaired inhibition of pain pathways may contribute to visceral 
hypersensitivity in IBS.26With regard to infection, one third of IBS cases develop their symptoms 
after an infectious gastroenteritis.27 Although this finding suggests an infectious aetiology, 
psychosocial stressors were the most important predictors of post-infectious IBS in a well 
designed prospective study.28
 Psychosocial factors have been widely studied in IBS. Recent reviews conclude with four 
general observations: 1) Psychological distress exacerbates symptoms of IBS, and more lifetime 
and daily stressful life events are reported and are strongly associated with symptom onset and 
severity, 2) Psychological and psychiatric comorbidity is common in patients with IBS, with 40-
90% classifying for mood disorders in specialist health care. Other associated psychological 
features are personality style (e.g. neuroticism), psychological distress, altered health beliefs, 
cognitions and coping style. 3) Psychosocial features, such as abuse, stressful life events or 
psychiatric disorder affect health status and clinical outcome. 4) Psychosocial factors influence 
which patients consult physicians, which tends to overestimate the true prevalence of 
psychosocial disturbance. 29-31 Furthermore, psychological profiles in subjects with IBS who do 
not consult have been found to be identical to the normal population. 32;33
These observations have resulted in a prevailing opinion that psychosocial factors are not 
associated with IBS per se, but have an important role in modulating the illness experience and its 
clinical outcome.30 However, the evidence is conflicting with two studies having demonstrated a 
higher prevalence of mood disorder also in subjects with IBS who do not consult. 34;35
Prevalence of IBS 
IBS is a world wide and highly prevalent phenomenon with a female predominance which 
appears to affect about a billion adults. The first population survey of functional gut symptoms 
(1980) found IBS in 14% of adults in Bristol, UK.36 Other studies from around the globe have 
demonstrated prevalences of IBS between 3% and 65%.9 This wide variation in prevalence seems 
to be more dependent on definitions and criteria used than geographical differences, with the 
Rome criteria providing the lowest prevalence estimates. 9;37 In a population based survey of 
Norwegian adults (Tromsø, 1980), 8% of males and 13% of females reported symptoms 
- 10 - 
suggestive of IBS (e.g. cramping pain and bloating).38 No studies have formally addressed the 
prevalence of IBS by the use of well defined criteria in a Norwegian adult population.  
Diagnosis of IBS  
Diagnosing IBS in clinical practice remains a challenge in the absence of a diagnostic marker. Yet, 
the importance of a precise diagnosis of IBS is underscored by its high prevalence both in 
primary and secondary health care. Since no diagnostic test is available, the diagnosis of IBS must 
be based on symptoms. Two highly different approaches are possible. 
 The diagnosis by exclusion approach permits the diagnosis only after extensive 
investigation has excluded all disease that could possibly cause the symptoms. In view of the 
complexity of IBS, it is understandable that this approach has been adopted by some doctors. 
However, this approach can result in extensive diagnostic testing which can cause unnecessary 
inconvenience and harmful complications to the patient and substantial strain on health care 
budgets. Pulling the diagnosis out of the “bottom drawer” when investigations have repeatedly 
proved negative is also unlikely to provide proper reassurance.
A positive symptom based approach is recommended as the preferred way of diagnosing 
IBS.6;39 Physicians can diagnose IBS by recognizing certain typical symptoms, checking for alarm 
symptoms, performing a physical examination, and undertaking individualised diagnostic testing. 
This approach permits a reliable diagnosis without extensive testing in most cases, and facilitates 
the explanation and reassurance which are cornerstones in the clinical handling of patients.
Symptom based criteria could facilitate a diagnosis based on symptoms and current 
guidelines recommend the use of the Rome II criteria.39  However, the diagnostic criteria for IBS 
were developed primarily for clinical and epidemiological research and they have not been 
validated in clinical settings. Therefore, we do not know whether the criteria are applicable in 
clinical practice or whether current knowledge about IBS, based on studies employing strict 
criteria, can be transferred to patients diagnosed with IBS in clinical practice. Importantly, if data 
from research are to be applied in clinical practice, diagnoses in research and clinical practice 
must be comparable or, ideally, identical.40
Characteristics of subjects with IBS
There is great variation in the clinical expression of symptoms from mild abdominal symptoms 
without apparent negative consequences for the individual to severe and disabling symptoms in a 
subset of patients. Patients with IBS are also characterised by somatic comorbidity, psychosocial 
problems, reduced quality of life and increased use of health resources.30;41;42 Health related quality 
of life in referred patients with moderate to severe IBS is markedly reduced and at level with 
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diseases such as heart failure, diabetes mellitus and depression.42;43 The burden of illness in IBS 
has been estimated to be $1.6-10 billion in direct and $19.2 billion in indirect costs.44;45 Thus, IBS 
is considered to represent a major burden for the individual patients and the community. 
Different viewpoints of IBS 
Perceptions about IBS and its’ characteristics are influenced by the viewpoints of health care 
providers and researchers. Only half of subjects with IBS consult physicians and less than ten 
percent of subjects with IBS are referred to specialists.2 Consultation behaviour is influenced by 
demographic factors, symptom severity, psychological factors and organisation of health care.30
Therefore, GPs, gastroenterologists, gynaecologists, surgeons and mental health care providers 
encounter different populations of patients with IBS. The majority of studies have been 
performed in subsets of referred patients willing to enter research. These studies have limited 
external validity and may have resulted in a distorted view on IBS. 
Comorbidity in subjects with IBS 
An intriguing feature of patients with IBS is that they are about twice as likely as comparison 
groups to be diagnosed with a variety of other somatic and psychiatric disorders. A recent 
systematic review of studies mainly performed in referred patients with IBS conclude that 
somatic disorders such as fibromyalgia, chronic fatigue syndrome, temporomandibular joint 
disorder and chronic pelvic pain are reported by 14%-35%, gastrointestinal disorders such as 
functional dyspepsia and GERD by 30%-60% and psychiatric disorders such as mood disorder 
by 40-90%.41 In contrast, IBS does not seem to be clearly associated with organic diseases such as 
cardiovascular disease, diabetes mellitus or other autoimmune diseases. These observations have 
raised questions whether IBS is part of a functional somatic syndrome and whether the diagnostic 
entity of IBS could be an artefact of specialisation.46 The systematic review has addressed this 
issue by multivariate analyses and concludes that IBS most likely is a distinct symptomatic 
entity.41 However, the strong comorbidity suggests a common feature important to the 
expression of these disorders, which is most likely psychological. Moreover, the comorbidity of 
IBS has possible implications for aetiology, diagnosis and treatment and might be important in 
explaining the observed suffering associated with IBS (see discussion).
Treatment of subjects with IBS 
Effective management of IBS presents major challenges. In the absence of a causative 
mechanism, symptomatic and supportive care can be the only realistic goal. Therefore, an 
effective doctor-patient interaction is considered crucial in the clinical handling of patients with 
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IBS.13 Given the large variation in patients’ symptoms and disability, a graded general treatment 
approach is recommended.6 A confident diagnosis is considered the cornerstone in this approach 
and could be, through patient reassurance and education, a powerful therapeutic tool in IBS.6;47
Identification of psychosocial stressors such as fear of cancer, psychiatric disease or chronic 
negative stress has a positive effect on the course of IBS and consultation behaviour.8 In a 
Norwegian survey, a large proportion of patients with somatic reasons for consulting GPs 
reported psychosocial problems which influenced on their health, but less than half of these 
problems were detected by their GPs.48 Patient education by self help guide books has recently 
been shown to reduce consultations for IBS and perceived symptom severity.49;50 Targeted 
treatment towards specific psychological or biological disturbances can be restricted to the few 
with severe and disabling symptoms where the general treatment approach and lifestyle 
interventions offer no significant relief.
Specific therapies for IBS are generally directed at gastrointestinal motor, sensory or 
central nervous system processing. Both drug and non-drug treatments are available. Dietary 
advice is also recommended although the evidence of efficacy is sparse.47;51-53 Alternative 
treatment such as acupuncture is probably widely used but the efficacy of such treatment is 
uncertain.54;55
Drug treatment in IBS has been disappointing and is hampered by side effects. According 
to systematic reviews and a recent meta-analysis, placebo seems to be the most effective 
treatment in IBS with a 20-50% placebo response in clinical trials.56-58  Limited therapeutic gains 
of 15-20% are observed for the few drugs with proven efficacy in subsets of patients with IBS in 
high-quality randomised trials. These drugs include tricyclic antidepressants in low doses 
(amitryptilyn, desipramine, clomipramine), serotonin agonists (tegaserod) or antagonists 
(alosetron).59-61  Furthermore, Loperamide is effective in relieving diarrhoea and urgency in IBS.62
Bulking agents as well as antibiotics and probiotics lack evidence of efficacy in IBS.63 A range of 
novel drugs targeted at the disturbed sensitivity or motility in IBS are in the pipeline.
 Psychological treatment has been widely studied in IBS. As with drug therapies, the 
effects on IBS symptoms are most often moderate and limited to subgroups of patients.64;65 Gut 
focused hypnotherapy is a particularly effective treatment option in patients with severe IBS. 
Such psychological treatment has the potential advantage of exerting beneficial effects on more 
than specific symptoms of IBS. For example, gut focused hypnotherapy also reduces the 
psychiatric and somatic comorbidity of IBS which might contribute to the observed long lasting 
beneficial effects on quality of life and use of health resources.66;67 The mechanisms by which 
hypnotherapy works remains to be understood, but recent research suggests that it exerts 
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physiological effects on colonic motility, visceral hypersensitivity and central processing of 
painful stimuli from the gut.68-70Cognitive behaviour therapy (CBT) is another treatment option 
with additional beneficial effects which has recently been shown effective also in patients with 
IBS in general practice.71 A major limitation of hypnotherapy, CBT and other psychological 
interventions is their demand of considerable resources and their current unavailability in clinical 
practice.
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AIMS OF THE STUDY 
The following aims correspond to the four publications in this thesis.
Paper I: To investigate the prevalence of abdominal complaints in general practice and the 
spectrum of diagnoses made by GPs, and to compare characteristics of patients diagnosed with 
functional gastrointestinal disorders (FGID) with those diagnosed with organic diseases. 
Paper II: To assess the agreement between the GPs´ diagnosis of IBS and the diagnosis of IBS 
according to the Rome II criteria. Furthermore, agreement was assessed for the diagnosis of 
functional bowel disorders (FBD), which is a generic term for IBS, functional diarrhoea, 
functional constipation and functional abdominal bloating, to investigate whether a broader 
definition of bowel disorders altered the agreement. Possible explanatory factors in cases of 
diagnostic discrepancy for IBS were also explored. 
Paper III: To explore characteristics, and in particular to measure comorbid symptoms, in 
patients with IBS in general practice. Secondly, we aimed to answer the following research 
question: Do patients with low, intermediate and high levels of somatic comorbidity constitute 
subgroups with different characteristics, natural course of symptoms and health care seeking 
behaviour?
Paper IV: To measure the prevalence of IBS in a Norwegian adult population, as defined by the 
Rome II criteria, and to explore possible differences in characteristics between 1) subjects with 
IBS and subjects without IBS and 2) IBS consulters and IBS non-consulters, with emphasis on 
comorbid somatic and psychological symptoms. We specifically hypothesised (post hoc) that the 
observed associations between IBS and global health, working disability, use of health care and 
medications were confounded by comorbid symptoms and disorders. 
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MATERIALS AND METHODS
This thesis is based on two cross-sectional studies (of which one included a prospective design) 
performed during 2001 in the county of Oppland:  The “Study of IBS in General Practice” 
(papers I-III) and the “Survey of IBS in the general population” (paper IV). The materials and 
methods used in these two studies are presented separately. Methodological limitations are mostly 
reserved for the general discussion. 
Study of IBS in general practice  
Study design 
This observational prospective multi-centre study was designed to identify and follow up a 
representative sample of patients with IBS in Norwegian general practice. The study was carried 
out during 2001 in the western region of Oppland county, which comprises 110 000 inhabitants 
served by 99 GPs and one hospital (Innlandet Hospital Health Authority, Gjøvik). In Norway, 
patients must seek health care through their locally assigned GP. The study consisted of four 
parts (part 1-4) as outlined in figure 2.
Figure 2: Flow chart of the “Study of IBS in general practice”
                    
Consecutive  patients  
N=3369 
p ĺ Unwilling N=277
Completed Questionnaire 
N=3092 
p ĺ No abdominal complaints N=1593
Abdominal complaints 
(AC) 
N=1499 
p ĺ AC Non-consulters N= 669 
Screening in the 
waiting room: 
Short 
questionnaire  
Had consulted or wish to 
consult for AC 
N=830 
 / p \
GP consultation   Rome II criteria palm 
p p
 GP diagnosis   Rome II diagnosis 
Part 
1
Part 
2
 \  /  
GP diagnosis and RII 
diagnosis 
N=553 
   p
Rome II IBS 
N=208 
Part 
3
Thorough 
characterisation 
by questionnaires p ĺ Drop outs N= 42 
Part 
4
Interview with 
questionnaires
Follow up  6-9 months 
N=166 
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Part 1 was performed during 10 days of practice for each participating GP. Consecutive 
patients consulting their GP were asked to complete a brief questionnaire in the waiting room 
(see appendix). Patients who reported abdominal complaints, for which they wished to consult or 
already had consulted, were invited to participate in part 2. 
In part 2 of the study, patients completed an electronic questionnaire in the waiting room 
which assessed gastrointestinal symptoms based on the Rome II criteria for FGID. Patients then 
consulted their GP as planned. After the consultation, the GP reported their diagnoses of the 
abdominal complaints in the electronic questionnaire, blinded to the patients’ answers. The GPs 
were instructed to manage their patients according to ordinary clinical practice, with no special 
attention to the study, and they received no formal information about IBS.  
In part 3 of the study, patients with Rome II IBS were thoroughly characterised by 
questionnaires, completed immediately after the consultation. 
In part 4 of the study, which had a prospective design, patients with Rome II IBS were 
invited to a follow up visit with practice staff after 6-9 months. Gastrointestinal symptoms were 
reported in the electronic questionnaire and use of health resources were assessed from the 
computerised health centre records. Patients received no specific attention during follow up.  
Patients
The target population was adult consulters for abdominal complaints in Norwegian general 
practice, as opposed to non-consulters. We therefore recruited consecutive patients in selected 
general practices in the county of Vest-Oppland, with current abdominal complaints for which 
they had consulted or wished to consult their GP. Informed consent was required in all parts of 
the study. Exclusion criteria were acute disease requiring immediate attention by the GP, major 
psychiatric disease or language problems.  
The material for paper I consisted of patients included in study part 2, who had consulted 
or wished to consult for abdominal complaints during the current consultation (main or 
additional problem).
The material for paper II consisted of patients in study part 2 with complete data in the 
electronic questionnaire (allowing a Rome II diagnosis) and with a diagnosis for the abdominal 
complaints made by their GP.   
The material for paper III consisted of patients with IBS (Rome II) included in study part 
3 and 4. Patients were excluded if the GP, based on all available information, had knowledge of 
organic disease to explain their symptoms. 
 The flow of patients in the different parts of the study is outlined in figure 2. More 
detailed flow charts are given in papers I-III.
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General practitioners 
Different practices in the county of Oppland were selected to obtain a variety of GPs, practice 
types and patient profiles. Only practices with available practice staff to perform the data-
collection (see below) were invited to participate. In all 26 GPs, working in 9 (out of 12 invited) 
general practices participated in the study. Four practices had two GPs, three had three GPs, one 
had four GPs and one had five GPs. Two practices were located in a town with 18000 
inhabitants (Gjøvik), seven were located in the countryside. Of the 26 participating GPs (20 M 
and 6 F, median age 45 years [range 26-68]), 15 were specialists in general practice and the 
median number of years in general practice was 10 (range 0-20).  
Measurement 
Patients completed questionnaires which assessed sociodemographic variables (such as adverse 
life events and working disability), gastrointestinal symptoms, comorbid symptoms, psychological 
factors and quality of life. GPs completed questionnaires of some patient-characteristics and 
diagnoses of abdominal complaints in their patients.
Gastrointestinal symptoms within the past three months were reported in the electronic 
questionnaire. Questions were based on the Rome II criteria (original criteria and the modular 
questionnaire, respondent form) for the following FGID: Functional heartburn, functional 
dyspepsia, IBS, functional diarrhoea, functional constipation and functional abdominal bloating.5;6
The Rome II criteria assess symptoms over the past year, but we used a three month time frame 
which is recommended for research purposes. The process of translating the questions into 
Norwegian included several revisions by experienced gastroenterologists and clinical researchers 
(see appendix for questions in Norwegian). The electronic questionnaire also assessed duration 
(more than one year), severity (mild/ moderate/ severe) and frequency (number of days per 
week) of abdominal pain/discomfort. An abdominal pain/ discomfort score was created by 
adding the severity and frequency of pain/ discomfort (range 0-12). Two questions assessed the 
relation between abdominal complaints and stress/ psychological factors (“stress-related 
symptoms”) and patients´ fear of cancer or other serious disease. GPs reported whether the 
patient was known from earlier consultations, whether a new consultation for abdominal 
complaints was scheduled, and the number of visits (0/1-5/>5) for abdominal complaints during 
the past two years.
A GP diagnosis for the abdominal complaints was reported. If the abdominal complaints 
had been sufficiently evaluated, the GPs reported their diagnosis by choosing one option from a 
list of clinically relevant diagnoses within three predefined categories (FGID, organic 
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gastrointestinal disease or other disease) (see diagnostic options in paper II). In order to evaluate 
the reliability of the diagnoses, the GPs were asked whether their diagnosis was considered to be 
verified or not. The GPs were instructed to interpret “verified” meaning that for the FGIDs, they 
had no evidence of organic disease, and for the organic diseases, that tests had confirmed organic 
disease.
Comorbid symptoms were assessed by the SHC (Subjective health complaints) inventory 
(see appendix). This questionnaire consists of 29 questions concerning severity and duration of 
subjective somatic and psychological health complaints during the preceding 30 days. The SHC 
does not map attributions or medical diagnoses for the complaints and is a systematic, easy and 
reliable way to score subjective health complaints.72 We created a somatic comorbidity score by 
adding the scores of 17 items concerning somatic symptoms (see paper III for more details). A 
reference material for the subjective health complaints assessed in patients with IBS was made 
available by SHC data from a Norwegian normal population, consisting of 1240 adults (53% 
females, mean age 41 years) included in a cross-sectional survey in Norway during 1996.73
Psychological factors were assessed by validated questionnaires. Psychological distress 
was measured by a 10 item version of the Hopkins Symptom Check list (SCL-10) with the 
intensity of each symptom graded from “not at all” to “extremely”. The average item score is 
often used as a measure of psychological distress, with a cut off point of 1.85 recommended as a 
valid predictor of mood disorder (anxiety/ depression).74 Health anxiety was measured with the 
Whitely index which consists of 14 questions, with the intensity of each symptom graded from 
“not at all” to “a great deal”.75 The personality trait neuroticism was measured by ten items in the 
Eysenck Personality Questionnaire (EPQ-10).76
Health related quality of life (HRQoL) was measured by Short form-12 (SF-12), with 
summary physical (PCS) and mental (MCS) component scores. The SF-12 appears to be a 
practical alternative to the widely used SF-36, with available population based results in Norway.77
Data-collection
Challenges of conducting clinical research in general practice include recruiting representative 
samples and to avoid distorting the diagnoses or interventions given by occupying time and 
attention from GPs in their busy clinical settings.78 In a meeting with GPs before the study, it 
became clear that successful data-collection in our study would require other study personnel 
than the GPs. Therefore, experienced members of the practice staff, who could be released from 
other duties during the study period, were made responsible for conducting the study in the 
participating centres.  We emphasized detailed information, motivation and education of study 
personnel and monitoring of data-collection throughout the study period. All participating GP 
- 19 - 
and practice staff received specific education about the study protocol and practical procedures. 
Written instructions about the collection of data, including how to complete the electronic 
questionnaire, were distributed. Monitoring of data-collection was performed every second week 
by the project leader. At the monitoring visits, data from handheld computers were synchronised 
into a lap top computer data-base allowing control of insufficient data-entry. Screening lists and 
Case Report Forms (CRF) were also monitored and checked for missing data. Practice staff 
contacted the project leader by telephone immediately if technical or other problems occurred.  
Data were collected by the above mentioned questionnaires. We chose to use an 
electronic questionnaire to facilitate data-collection and to permit the Rome II diagnosis to be 
available immediately after the consultation. This questionnaire was administered on a handheld 
computer (palm m100®), programmed (Pendragon Forms ®) to classify diagnoses according to 
the Rome II criteria for FGID. The questions were presented one by one on the screen, requiring 
an answer before the next question was presented. Patients entered their answers by touching the 
corresponding buttons on the screen, assisted by practice staff if necessary. Handheld computers 
have shown to be well accepted by patients, with good data quality and reliability in various 
clinical settings.79
Survey of IBS in the general population  
Study design and material
This cross-sectional population based survey was conducted as part of the OPPHED (Oppland 
and Hedmark) health study in 2001, performed by the National Health Screening Service (NHSS) 
of Norway. The NHSS have been responsible for similar surveys in different regions of Norway 
over the past 30 years. The director of the NHSS invited local research groups to participate with 
separate research projects in the OPPHED study. We participated with our questionnaire 
regarding IBS.  
 All men and women in selected age groups (born in 1970, 1960, 1955, 1940 and 1925) in 
the county of Oppland (180 000 inhabitants) were invited by mail to participate in the OPPHED 
survey. Subjects completed questionnaires in a bus located nearby their place of living. All 
subjects attending the survey were invited to answer our additional questionnaire regarding 
gastrointestinal symptoms. This questionnaire was completed at home and returned to the NHSS 
by mail. Non-responders received two reminders. Non-responders were compared with 
responders with regard to age-group and gender (the only available variables in non-responders).  
Of 11078 adults invited to the OPPHED survey, 4622 (42%) completed our questionnaire and 
388 had IBS (8.4%) according to the Rome II criteria (figure 3).
- 20 - 
Figure 3: Flow chart of subjects in the “Survey of IBS in the general population”
Invited OPPHED (Oppland)  
N= 11078 
Ļ ĺ 4880 – Did not attend the survey 
Participated in the survey 
 N=6198 (56%) 
Ļ ĺ 1576 –Did not return “ GI  questionnaire” 
Completed GI questionnaire 
N=4622 (42% of invited) 
Ļ ĺ
3742- No abdominal pain/ discomfort 
Abdominal  pain/ discomfort within 3 months 
N=1268 (27% of included) 
Ļ ĺ
880- Other abd. complaints (non IBS) 
IBS ( Rome II criteria) 388 (8.4%) 
Measurement 
Gastrointestinal symptoms were assessed in a paper questionnaire with 26 items regarding 
specific bowel symptoms, allowing a Rome II diagnosis for IBS as well as assessment of duration, 
severity and frequency of abdominal pain/ discomfort and earlier visits to physicians for 
abdominal complaints. The questions were similar to the questions used in the general practice 
study, as described above and shown in the appendix.   
The original NHSS questionnaire, as well as a translated English version, is available at 
www.fhi.no/tema/helseundersokelse/oslo/index.html. Questions were asked about socio-
demographic variables, including civil status, years of education, working status, current global 
health status (rated: poor, not quite good, good, very good) somatic and psychiatric comorbidity 
and use of health resources. 
Somatic comorbidity was assessed by six questions regarding musculoskeletal complaints 
(MSC) within the last four weeks (neck/shoulder, arms/hands, upper back, lower back, 
hip/legs/feet and other locations) with the intensity of each complaint rated as none, some, 
severe. A MSC-score was calculated by summarising the scores of each item (range 0-12). Current 
or earlier presence of fibromyalgia/chronic pain syndrome was also reported.
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Psychiatric comorbidity was assessed by the SCL-10 (as described above) and one 
question regarding presence of earlier or current mental problems for which the subjects had 
applied help. 
Use of health resources was measured as the number of health care visits (0/1-3/ 4 or 
more) within the last year to general practitioners (GPs), psychiatrists/psychologists, other 
specialists and alternative health care providers, and the use of medications (analgesics over the 
counter and antidepressants) during the last month (none/ less than weekly/ weekly but not 
daily/ daily). 
Data analysis 
All statistical methods applied were performed in the SPSS statistical package v.10/v.11 and 
StatXact. Continuous variables were checked for distribution and results were given as mean with 
standard deviations (SD) or median with range. Categorical variables were presented as 
proportions, numbers or percentages. Comparisons between groups were performed with 
bivariate and multivariate analyses. Bivariate analyses were done by Chi-Squared, Mann-Whitney 
U, Student t or ANOVA tests. Multivariate analyses were performed by stepwise logistic 
regression, with variables with p-values <0.20 by bivariate analysis entered in the models. Results 
concerning differences between groups were preferably reported as Odds Ratios (OR) with 95% 
confidence intervals (CI) for categorical variables and with mean (SD) and p-values for 
continuous variables.  For within group comparisons, we used the Kolmogorov-Smirnov test (or 
one sample t-test). Analysis of agreement was performed by kappa-statistics (paper II). Age and 
gender adjusted analyses of prevalence estimates were performed (paper IV). Correlation analyses 
of normally distributed continuous variables were performed by the Pearson r-test (paper III).
Ethical aspects 
The studies were performed according to the Declaration of Helsinki, and approved by the 
Regional committee for Medical Research Ethics and the Data Inspectorate, Oslo, Norway.
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SUMMARY OF RESULTS 
Paper I- Abdominal complaints in general practice: Diagnoses and characteristics of patients
Abdominal complaints were reported by 1499 of 3092 consecutive patients. 460 patients (15% of 
screened) wished to consult for their complaints, of which 392 patients were further 
characterised. GPs diagnosed FGID in 167 (43%), organic disease in 145 (37%) and made no 
diagnosis in 80 (20%). IBS constituted the most frequent diagnosis (13%), followed by GERD 
(10%) and no malignant disease was diagnosed. 128 of the 312 diagnosed patients had a verified 
diagnosis. None of the 26 GPs used symptom based criteria to diagnose the FGID.  
Although a common reason for consultation, the abdominal complaints were seldom of severe 
intensity (15%) and a minority (9%) had consulted their GP for such complaints more than five 
times during the last two years. Yet, 39% feared that abdominal complaints could be due to 
cancer/serious disease, independent of a diagnosis of FGID or organic disease. 
 We could largely not confirm our hypothesis that characteristics of patients could 
distinguish FGID from organic diseases. Stress-related symptoms was a predictor of a FGID 
diagnosis (OR 1.95[95% CI: 1.2-3.1]) and weight loss predicted in addition organic disease in the 
subset with verified diagnoses (OR=2.7[95%CI: 1.1-6.7]). No significant differences between 
FGID and organic diseases were observed with regard to age, gender, intensity or frequency of 
abdominal pain/ discomfort, number of visits for abdominal complaints, fear of cancer or alarm 
symptoms such as blood in stools, nocturnal symptoms or milk intolerance.   
Paper II- Diagnosing Irritable Bowel Syndrome: Poor agreement between general practitioners and the Rome II 
criteria
In this study, 553 consecutive patients with abdominal complaints were diagnosed by their GP 
and had complete data in the Rome II electronic questionnaire. Of these patients, 107 had IBS 
according to the GPs and 209 had IBS according to the Rome II criteria (agreement 58%, kappa 
0.01 [95%CI: -0.06; 0.09]). Similar levels of agreement were found for the diagnosis of FBD 
(49%, kappa 0.05[95% CI: 0.003; 0.13]). Agreement for the diagnosis of IBS and FBD remained 
poor in subgroups of patients without organic disease, without reflux or dyspepsia and in patients 
with a verified diagnosis (45%-58%, kappa -0.02 to 0.13). These subgroup analyses suggest that 
the poor agreement can not be explained by methodological issues. Unexpectedly, IBS and FBD 
cases were identified more often by the Rome II criteria than by the GPs in all these groups of 
patients. In patients with diagnostic discrepancy concerning IBS, stress-related symptoms 
predicted a diagnosis of IBS made by the GPs only (OR=2.2 [95% CI: 1.1-4.2]).  Our findings 
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imply that current knowledge about IBS based on strict criteria is not necessarily transferable to 
patients diagnosed with IBS by their GP.  
Paper III- Comorbidity of Irritable Bowel Syndrome in general practice: A striking feature with clinical 
implications
In this study, 208 patients with IBS (Rome II) were included and thoroughly characterised. 
Patients with IBS reported 20 of 22 comorbid symptoms significantly more frequent than a 
population based reference material of 1240 adults (odds ratios in the range 2-7,p<0.001). Three 
groups of patients with low (n=42), intermediate (n=100) and high somatic comorbidity (n=61) 
were identified by a somatic comorbidity score (17 somatic symptoms in the SHC inventory). 
This score was normally distributed, significantly higher in patients with IBS than in controls 
(mean 13.0 [SD 8.1] and 5.8 [SD 5.1], p<0.001)) and correlated with psychological distress (SCL-
10) (R=0.46, r2 =0.22, p<0.001). Patients with high somatic comorbidity were characterized by 
high levels of psychological distress (mood disorder present in 63%), health anxiety, neuroticism 
and adverse life events as well as reduced quality of life and increased use of health resources, 
when compared to those with low and intermediate somatic comorbidity (p<0.05 for all 
comparisons). The intensity of abdominal pain/ discomfort did not differ significantly between 
groups. Some other characteristics of patients with IBS can be noted: 13% of patients with IBS 
reported severe abdominal pain, 20% reported abdominal pain/ discomfort more frequent than 
five days per week and 7% had consulted for IBS more than five times within two years. Nine 
out of ten patients reported presence of abdominal pain/ discomfort after 6-9 months. The mean 
number of visits to GPs in the follow up period was 3.7 (SD 2.9) but only 20% had consulted 
their GP for IBS. 
Paper IV- Prevalence, comorbidity and impact of Irritable Bowel Syndrome in Norway
388 of 4622 included subjects (8.4% [95%CI: 7.6-9.4%]) had IBS according to the Rome II 
criteria.  The prevalence of IBS was higher in women and decreased with age. The proportion 
who had consulted for IBS (IBS consulters) increased with age, from 51% among 30 year olds to 
79% in 75 year olds (p=0.05). IBS was associated with musculoskeletal complaints (OR= 2.4-3.4 
for six different items), fibromyalgia (OR=3.6 [95% CI: 2.7-4.8]), mood disorder (OR=3.3 
[95%CI: 2.6-4.3]), reduced global health (OR=2.6 [95%CI: 2.1-3.2]), working disability (OR=1.6 
[95%CI: 1.2-2.1]), more frequent health care visits (OR 1.7-2.3) and use of medications 
(OR=2.3). When controlling for comorbidity, only reduced global health (OR=1.5[95%CI: 1.1-
2.0]) and use of alternative health care (OR=1.7[95%CI: 1.3-2.4]) remained associated with IBS. 
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The severity of abdominal pain/ discomfort independently predicted earlier consultations for IBS 
(OR= 1.3[95%CI: 1.2-1.5]). This first formal community survey of IBS in Norway demonstrates 
that IBS is a common chronic disorder which leads to consultations for most in the long run. 
Somatic and psychiatric comorbidity are common features of IBS which play a main role in 
explaining the reduced health and increased use of health resources reported by subjects with 
IBS.
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GENERAL DISCUSSION 
Prevalence of IBS in the general population (paper IV) 
IBS is truly a common disorder with an overall prevalence of 8.4% (95%CI: 7.6-9.2) in the county 
of Oppland, according to the strict Rome II criteria. The observed prevalence and its’ age 
dependent decrease as well as the female predominance harmonise with findings from other 
countries.1;12;80;81 Prevalence estimates of Rome II IBS do however vary, with the lowest from 
Spain (2.9%) to the highest in Canada (12.1%) and intermediate estimates from eight European 
countries (9.6%), Finland(5.1%) and Australia (6.9%).3;12;37;82;83The observed differences in Rome 
II prevalence estimates could represent geographical variations as suggested by the European 
study, or methodological aspects related to sampling procedures or translation of criteria.3 A 
methodological problem with the European study is that the reported prevalence rates comprised 
two populations of IBS subjects, those with a clinical diagnosis of IBS and those with IBS 
according to Rome II criteria. The problem with this approach is that a clinical diagnosis of IBS 
is not necessarily in agreement with a criteria based diagnosis, as shown in our general practice 
study (paper II). 
 Although widely recommended for epidemiological surveys of IBS, the Rome II criteria 
are not perfect. Some argue that they are too strict, supported by higher prevalence estimates 
obtained by the Rome I criteria and Manning criteria.82;83 This discrepancy highlights a major 
problem with defining disorders such as IBS. The intensity and frequency of IBS symptoms 
probably display normal distributions in the population which makes a meaningful cut-off point 
difficult to determine. Moreover, the selection of symptoms used to identify IBS also impact on 
prevalence estimates. This can be exemplified by the former population based survey of IBS in 
Norway (adults aged 20-55 years, Tromsø, 1980) which reported symptoms suggestive of IBS in 
8% of men and 13% of women.38 Since these estimates are strikingly similar to our age and 
gender adjusted prevalence estimates (see figure 1, paper IV) one could infer that the prevalence 
of IBS in Norway has remained unchanged since 1980. However, criteria used to identify IBS 
differ in these two surveys. In the Tromsø survey, the two questions used to diagnose IBS were 
as follows: “Do you often suffer from cramping abdominal pain?” and “Are you often bothered 
by bloating and abdominal rumbling?”. All diagnostic criteria for IBS, including the Rome II 
criteria, require abdominal pain/ discomfort associated with a disturbed bowel habit (e.g. 
diarrhoea or constipation). The lacking assessment of a disturbed bowel habit, which is a main 
symptom feature in IBS, is a major limitation of the former Norwegian survey. 
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 Most scientific papers and textbooks about IBS state that only a minority of subjects with 
IBS consult physicians.1;84 We found that more than half of subjects with IBS had consulted a 
physician for their abdominal complaints, increasing to 79% in the 75 year olds. Similar findings 
has been reported from Australia and contrasts with the general assumption that a minority will 
consult.34 Whether our findings reflect geographical differences or a general increase in 
consultations for IBS remains unanswered. Differences in health care systems could be a major 
determinant of consultations for IBS. In Norway, the public health care system has high 
accessibility and low costs for the patient which might lower the threshold for consulting. 
Abdominal complaints and IBS in general practice (paper I) 
We confirm that patients presenting with abdominal complaints constitute a significant workload 
for GPs.2;85 Our finding that 15% of patients attending their GP consulted or wished to consult 
for these symptoms is higher than what has been reported from the UK.2 In our study, 
abdominal complaints were not necessarily primary reasons for consultation which could explain 
some of the discrepancy with the UK study. Nevertheless, we demonstrate that many patients in 
general practice have a need to consult for abdominal complaints, supported by our finding that 
most adults with IBS in the population will consult in the long run (paper IV).
 In those who consult for abdominal complaints, GPs need to correctly diagnose the 
various disorders and diseases to provide proper treatment. As reported by others, GPs 
diagnosed a wide range of non-malignant disorders and diseases with the FGID constituting half 
of diagnoses and IBS being the most frequent diagnosis.2 The absence of malignant disease and 
the one percent with inflammatory bowel disorder in our study demonstrate what challenge it is 
for GPs to select patients for investigations such as colonoscopy. GPs might expect to see one 
new case and eight prevalent cases of IBS per week and one new case of colorectal cancer per 
year. 2;86 In the UK study by Thompson, few patients were referred to specialists and GPs used 
other characteristics (e.g. polysymptomatic, unexplained symptoms and long lasting abdominal 
complaints) to separate FGID from organic diseases. In our study, a distinction between FGID 
and organic disease based on characteristics of patients proved difficult. Although stress-related 
symptoms predicted a GP diagnosis of FGID, the clinical significance of this finding is 
questionable in particular with regard to exclusion of organic disease (as discussed in paper I). A 
weakness of our study is the limited selection of patient characteristics which did not include a 
thorough characterisation of abdominal symptoms. Guidelines suggest that identification of the 
typical abdominal symptoms within the various FGID syndromes is the key to a correct and 
confident diagnosis.6;39 We do not know to what extent GPs use such characteristics in their daily 
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practice, but the observed poor agreement in the diagnosis of IBS between GPs and Rome II 
criteria (as shown in paper II and discussed below) does not support that GPs strictly rely on 
these characteristics in the distinction between FGID and organic disease. 
 Symptoms of colorectal cancer, celiac disease and inflammatory bowel disease (IBD) 
might mimic symptoms of IBS. In this context, alarm symptoms are recommended to identify 
candidates for further diagnostic evaluation.39 However, most studies are based on referred 
patients and there is a lack of evidence with regard to the validity of alarm symptoms in general 
practice. We demonstrate that blood in the stools, abdominal complaints during night-time and 
intolerance to milk are reported as frequently by patients diagnosed with FGID as by patients 
diagnosed with organic diseases. The only alarm symptom which predicted organic disease was 
weight loss. However, this finding was only statistically significant in the subset with a verified 
diagnosis. A weakness of our study is the perhaps inaccurate distinction between FGID and 
organic disease, since different diseases have specific alarm symptoms attached to them. It has 
been suggested that questionnaires are suitable tools for assessment of alarm symptoms.87 We 
propose that a detailed assessment by an experienced doctor is more valuable. Undertaking 
validity studies of alarm symptoms in general practice is a huge task but should nevertheless be 
performed to clarify this issue. 
Diagnosis of IBS in general practice (paper II) 
Although most patients with IBS are handled by their GP without referral to specialists, little is 
known about how GPs diagnose IBS. In the UK, GPs say they diagnose IBS with reasonable 
confidence and less difficulty than other common, painful disorders.88 In the US, GPs were 
found to lack knowledge about the typical symptoms of IBS.89 Moreover, in the large European 
survey, only a minority of IBS consulters had been formally diagnosed with IBS with significant 
differences between countries.12 Our study provides further evidence that GPs are unfamiliar 
with diagnostic criteria for IBS, such as the Rome II criteria.2;90 We therefore explored whether 
GPs and Rome II criteria agreed on the diagnosis of IBS in a representative sample of patients 
with abdominal complaints.  
 Unexpectedly, we found poor agreement in the diagnosis of IBS between GPs and the 
Rome II criteria. Our finding is supported by others and implies that GPs and symptom based 
criteria identify different groups of patients with IBS.91 Importantly, current knowledge about IBS 
based on studies of patients who fulfil diagnostic criteria can not be transferred to patients 
diagnosed with IBS in general practice. This includes knowledge concerning characteristics of 
patients and efficacy of treatment.   
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 Another unexpected finding was that the Rome II criteria identified nearly twice as many 
cases with IBS than did the GPs. The Rome II criteria have been criticized for being too strict for 
clinical practice.83 We postulate that the Rome II criteria are more capable of identifying the 
typical symptoms of IBS than GPs, supported by the extensive body of research underlying the 
development of the criteria.6
 If GPs lack knowledge about the typical symptoms of IBS, how can they succeed with the 
recommended symptom based approach? In this context, acquisition of such knowledge could 
represent the greatest challenge to overcome for physicians in general, and for GPs in particular. 
A fact easily forgotten by specialists is that GPs encounter the whole spectrum of human 
disorder and disease in their practices. This poses a restriction on how much we can expect GPs 
to know about IBS. Another issue is to what extent GPs consider a positive diagnosis of IBS 
important. As with other medically unexplained physical symptoms, little time is probably 
devoted to IBS in pre- and post-graduate medical education in Norway.92 Yet, since GPs 
diagnose and treat most patients without referral, they need to learn more about IBS if to succeed 
with a positive symptom based strategy. We also need to learn more about how GPs diagnose 
IBS. 2;88
The role of diagnostic criteria for IBS in clinical practice remains unclear. Apart from 
being valid, the criteria need to be applicable in busy clinical settings. The Rome II criteria are 
primarily developed for research purposes and might be too complicated and time consuming in 
clinical practice.40 The Rome II committee offers no recommendations as to how the criteria 
should be applied in busy clinical practices.5 While criteria provide a platform for a positive IBS 
diagnosis, the clinical diagnostic process includes a complex mental search for structural disease. 
Therefore, questionnaires in clinical practice should probably be different from those employed 
in surveys or trials. It also remains unclear which criteria perform best in clinical practice. A 
Swedish group has evaluated a simple questionnaire for IBS which shows satisfactory agreement 
with Rome criteria..93 Hopefully, the Rome III criteria to be published in 2006 will further clarify 
the role of diagnostic criteria in clinical practice. So far, GPs have not participated in the 
development of diagnostic criteria for IBS and they have not participated in the Rome III 
process. It therefore remains to be seen whether these criteria will be tailored to fit in a general 
practice setting.  
Characteristics of subjects with IBS in the population and in general practice (paper III 
and IV)
Since most attention has been given to patients with IBS referred to specialists, our studies of 
subjects with IBS who do not consult and of patients seen by GPs provide a broader picture. The 
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overall impression is that most subjects with IBS have longstanding abdominal complaints of 
mild to moderate intensity which seldom disrupts daily activities. Although most will consult for 
symptoms of IBS in the long run, few had consulted their GP frequently for abdominal 
complaints. We confirm that symptom severity is a predictor for healthcare seeking in IBS (paper 
IV).30 In general practice, the natural course of IBS was remarkably stable in the short term but 
less is known about the natural course of IBS in the long term.7 In the population based survey, 
we observed a male predominance of diarrhoea symptoms and female predominance of 
constipation. Similar patterns have been demonstrated in IBS consulters.94-96
 We also found that IBS sufferers in the general population and in general practice were 
characterized by reduced global health, working ability and increased use of health care resources. 
In line with what is generally believed and published about IBS, we could have concluded that 
IBS leads to reduced quality of life and increased use of health resources.42;44 Such causal 
inferences are however vulnerable for confounding effects of unmeasured characteristics. 
Interestingly, patients consulted their GPs nearly four times during the following up period but 
only 20% had consulted for IBS. Our assessment of comorbid symptoms and disorders in IBS 
revealed a striking feature not to be overlooked.  
Comorbidity of IBS and its implications (paper III and IV) 
Prevalence
Although described twenty years ago as a common feature in IBS, comorbid symptoms and 
disorders are seldom taken into account in clinical or epidemiological research or in aetiological 
models to explain IBS.41;97 Again, most studies are based on referred patients. We provide novel 
evidence that somatic and psychiatric comorbidity is associated with IBS per se, and not merely a 
feature of its consulters. 
 In the general population and in general practice, the odds for reporting a range of 
somatic and psychiatric comorbid symptoms and disorders were two to seven times higher in 
subjects with IBS than in subjects without IBS.  To give the reader an example of what the 
observed levels of somatic comorbidity means, the average patient with IBS in general practice 
reported severe intensity of headache, low back pain and dizziness and moderate intensity of 
neck pain and sleep problems. Two other studies of IBS in general practice support our 
findings.91;98 Patients with IBS in general practice also frequently reported comorbid 
gastrointestinal disorders such as heartburn and dyspepsia, in line with what has been found in 
referred patients.41
 With regard to psychiatric comorbidity, mood disorder (as measured by the SCL-10) was 
reported by 38% of patients with IBS in general practice, by 25% of community subjects with 
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IBS and by 9 % of adults without IBS. The odds for reporting mood disorder was three times 
higher in subjects with IBS than in subjects without IBS. Our finding is supported by others and 
contrasts with the general assumption that non-consulters with IBS display similar psychological 
profiles as subjects without IBS.12;34;35;35 In a brain-gut disorder such as IBS, it should however not 
be surprising that psychology interplays with biology. 
 It is indeed common to experience somatic symptoms also in adults without IBS. In the 
Norwegian survey used as a reference material by us, headache was reported by 51% and low 
back pain by 40% of adults (paper III). Musculoskeletal symptoms along with mental disorders 
constitute the most frequent reasons for sick leave and disability pension in Norway, by far more 
frequent than symptoms of IBS.99;100 A reasonable question is what bothers patients with IBS the 
most: Their abdominal complaints or their comorbid symptoms and disorders?  
Impact of comorbidity
We largely confirmed our hypothesis that the comorbidity of IBS confounds associations 
between IBS and reduced health and increased use of health resources. Our hypothesis emerged 
from the picture provided by our division of patients in general practice with different levels of 
somatic comorbidity (paper III). Patients with IBS with few or none somatic comorbid 
symptoms reported apparently normal quality of life (SF-12), infrequent use of health resources 
and mood disorder at level with the general population in Norway. Those with IBS and excessive 
somatic comorbidity were characterised by markedly reduced quality of life, high levels of mood 
disorder (present in 61%), neuroticism, health anxiety, adverse life events and more frequent GP 
visits in the follow up period. Contrary to what we expected, the severity of abdominal pain/ 
discomfort did not differ significantly between patients with different levels of somatic 
comorbidity.
 These observations made us specifically address the possible confounding effects of 
somatic and psychiatric comorbidity in IBS by multivariate analyses in the population based 
survey (paper IV). As expected, presence of fibromyalgia and mood disorder contributed to and 
was more important in explaining the reduced global health reported by subjects with IBS. 
Furthermore, the comorbidity solely explained the reduced working ability and increased use of 
health resources, except use of alternative health care. The increased use of alternative health care 
associated with IBS could imply insufficient public health care for this group of patients. 
Unfortunately, alternative treatment is costly to the patient and lacks documentation of efficacy.55
 An increasing number of studies support that much of the suffering hitherto associated 
with IBS can be explained by comorbid symptoms and disorders.33;101-103 We conclude that the 
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comorbidity of IBS should be taken into account as a possible confounder in future attempts to 
measure the impact of IBS. Our results would have been strengthened by more comprehensive 
measurement of the most frequent comorbid disorders associated with IBS, severity of IBS and 
disease specific quality of life. With regard to the severity of IBS, a recent review suggests that it 
should be considered a multidimensional concept, not fully explained by intensity of 
gastrointestinal symptoms.104The multiple components to be considered are health related quality 
of life, psychosocial factors, consultation behaviour and burden of illness. Interestingly, we 
provide evidence that the comorbidity of IBS is associated with all these features. We suggest that 
the comorbidity of IBS, which by definition is a co-existing phenomenon, should be assessed in 
addition to the multidimensional components of IBS severity and adjusted for in attempts to 
measure the impact of IBS. 
Implications for aetiology and treatment 
The strong association between IBS and somatic comorbid disorders could help us with some of 
the greatest challenges in interpreting research on the nature and treatment of IBS. First, it would 
help explain why all of the specific and measurable characteristics of IBS patients, whether 
autonomous dysfunction, motility disturbance, or visceral hypersensitivity are absent in a 
substantial proportion of patients. Second, it would explain to some degree why most efforts to 
treat IBS, whether pharmacologic or psychological, benefit only about one half of the patients 
receiving the intervention.41
 With regard to gastrointestinal comorbidity, the substantial overlap between IBS, 
functional dyspepsia and GERD challenges the current paradigm that functional GI disorders 
represent multiple discreet entities.105;106 The most likely explanation for this overlap is shared 
pathophysiological mechanisms such as visceral hypersensitivity and motility abnormalities.41
 With regard to somatic and psychiatric comorbidity in IBS, the aetiological implications 
are not straightforward. Hitherto, the aetiology of IBS has most often been conceptualised in a 
biopsychosocial model which suggests that (1) many factors or influences contribute to symptom 
development, (2) no one of these factors are necessary to the development of the disorder, and 
(3) these factors interact in different combinations. Interestingly, this multidimensional model 
includes psychiatric comorbidity as a psychological factor but excludes somatic comorbidity. This 
issue is addressed in the systematic review of comorbidity in IBS and several proposed 
hypotheses are discussed (diagnostic ambiguity, neuroendocrine-immune, somatisation and the 
biopsychosocial model).41 Based on available evidence, the authors put forward a “dual aetiology 
hypothesis”, recently renamed “the heterogeneity hypothesis”: The IBS diagnosis is applied to a 
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heterogeneous group of patients, some of whom have a predominantly psychological aetiology, 
whereas others have a predominantly biological aetiology. The presence of multiple somatic 
comorbid disorders is a marker for psychological influences on aetiology. This somatisation trait 
could be the result of genetic factors, early life events, model learning or sensitisation 
mechanisms at different levels of the ENS and CNS. Accordingly, those with IBS without 
somatic comorbidity are more likely to have a predominantly biological aetiology. End organ (e.g. 
gut) dysfunction caused by altered neurotransmission, infection, inflammation or visceral 
hypersensitivity could play a major role for IBS symptoms in these patients.  
To our knowledge we were the first to test “the heterogeneity hypothesis” in patients 
with IBS (paper III). As described above, subgroups of patients with low, intermediate and high 
levels of somatic comorbidity clearly differed with regard to psychological problems, adverse life 
events, quality of life and use of health care. Moreover, a significant correlation was found 
between the number and intensity of comorbid somatic symptoms and psychological distress. 
Our findings lend support to the hypothesis, and suggest that subgroups of patients with 
different characteristics and needs of treatment can be identified by assessment of somatic 
comorbid symptoms.
However, there are some important limitations with this hypothesis. First, somatic 
comorbid symptoms represent a continuum which makes it difficult to separate patients with low 
and high levels of comorbidity in clinical practice. Accordingly, most patients reported 
intermediate levels of comorbidity, and displayed characteristics in between those with low and 
high comorbidity.  Second, in a heterogeneous and multifactorial brain-gut disorder such as IBS, 
the hypothesis is likely to be an oversimplification. Indeed, the term “dual aetiology” could easily 
be misinterpreted by biomedically oriented physicians and endanger the recommended holistic 
approach in IBS. Physicians need to evaluate each patient individually both with regard to 
biological and psychosocial factors to provide a general treatment approach. As pointed out by 
the authors, it is not the intention to label patients with either a psychological or biological 
aetiology, rather to point out a predominance of aetiological factors in subgroups of patients.41
The term “heterogeneity hypothesis” is therefore more appropriate and is now used by 
Whitehead and his research group (personal communication 2005).
 It is reasonable that patients with excessive somatic comorbidity will need different 
treatment than patients without such comorbidity. Moreover, the suffering subset with IBS and 
excessive somatic comorbidity in our general practice study seems to be in particular need of 
treatment, given their poor quality of life, working disability and increased use of health 
resources. In these patients, psychological interventions such as gut specific hypnotherapy, 
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cognitive behavioural therapy or tricyclic antidepressants could be effective treatment options. 
The long lasting effects on symptoms of IBS, comorbidity and quality of life by hypnotherapy are 
promising in this context.67 Less promising is the fact that gut directed hypnotherapy remains 
unavailable in Norway 20 years after it was proven effective in patients with IBS.66 Tricyclic 
antidepressants are probably more widely used by patients with IBS, but adverse effects could 
hamper their use in these patients.59
 In those with IBS and low somatic comorbidity (e.g. at level with the general population), 
targeted treatment towards specific symptoms of IBS could prove efficacious. How many of 
these patients who will want or need specific treatment can be questioned, given their apparently 
normal quality of life and limited use of health resources. This observation is of particular 
relevance in times when a range of new drugs targeted towards biological factors in IBS are in the 
pipeline.
 We conclude that the comorbidity of IBS has implications for aetiology and treatment 
and that the “heterogeneity hypothesis” is one possible way to conceptualise this striking feature: 
It might be more productive to look for subgroups of patients who fit a particular 
pathophysiologic mechanism or who respond to a specific treatment, rather than assuming that 
one aetiology and one treatment must characterise all patients.41 The hypothesis needs to be 
supported by research, with for instance randomised controlled trials of specific interventions in 
the proposed subsets of patients. 
Assessment of comorbidity: Useful in clinical practice?
We were impressed by the fact that patients with IBS in general practice reported 20 of 22 
symptoms more frequent than controls (paper III). However, GPs are not particularly impressed 
when I tell them about the aches, pains and psychological problems which characterise their 
patients with IBS: “Tell us something we don’t know!” is the classical reply. Nevertheless, it could 
be questioned whether physicians are able to capture the panorama of health complaints in 
clinical encounters with these patients. In this context, structured assessment of comorbidity 
could prove useful in particular for GPs responsible for general care of their patients, regardless 
of what organ system the symptoms are attached to. Such assessment could also be relevant for 
gastroenterologists who encounter patients with IBS and even higher levels of somatic and 
psychiatric comorbidity.41 To my experience, some of the most suffering patients with IBS 
attending our gastroenterology outpatient clinic have a lot more to worry about than their 
irritable bowel.107 Identification of excessive somatic comorbidity in these patients could prevent 
vicious circles with repeated diagnostic evaluations by a diversity of specialists and facilitate 
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identification of the above mentioned subgroups with different needs of treatment. It has also 
been suggested that comorbid symptoms can serve as additional symptoms to cumulatively 
support the diagnosis of IBS.108 Although GPs probably use these features in their diagnostic 
evaluation of patients with IBS, comorbid symptoms or disorders are not yet included in 
diagnostic criteria for IBS.2
 Structured assessment of comorbidity could be performed by questionnaires such as the 
SHC inventory or questionnaires specifically developed to assess comorbid somatic symptoms 
and disorders in IBS. The usefulness of such assessment in clinical practice remains to be 
determined.
Methodological considerations
Sources of random and systematic error 
In clinical and epidemiological research, random error can be handled by statistical methods. On 
the contrary, systematic errors such as selection bias, information bias and confounding can best 
be controlled for by proper study design and balanced interpretation of results.  
With regard to random error, calculation of sample size will reduce the possibility of type 
I and II error. A limitation of our studies is our rough estimates of sample size. In the general 
practice study, we aimed to screen 4000 consecutive patients to identify a representative sample 
with abdominal complaints and IBS. This calculation was mainly based on an assumed prevalence 
of IBS (Rome II) at 5%.  3092 patients were screened of which 460 consulted for abdominal 
complaints (paper 1), 553 were diagnosed by their GP and the Rome II criteria (paper II) and 208 
had IBS according to Rome II criteria (paper III). The risk for type II error is probably largest in 
the comparison of characteristics between patients diagnosed with FGID and organic disease, as 
discussed in paper I.  Random error is probably less likely in paper II-IV. The statistical methods 
used should control for other types of random error.   
Selection bias 
In cross sectional studies, sampling of representative study populations is crucial. The external 
validity of our findings depends primarily on whether adults both in general practice and in the 
general population of Oppland county (who constituted the population frame) systematically 
differ from the population of Norway at whole (target population), and whether those who 
participated in our studies (study population) systematically differ from those not included.
In the general practice study, we lost patients at each step of the study (see flow charts 
paper I-III and page x). We can not determine whether non-responders systematically differ from 
responders. Yet, it is reassuring that 92% of consecutive consulting patients answered the first 
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questionnaire and 88% of patients with abdominal complaints (for which they had consulted or 
wished to consult) satisfactorily completed the electronic questionnaire. Likewise, 85% of eligible 
patients were included in the first study (paper I), 88% of eligible patients were included in the 
second study (paper II) and 75% of eligible patients with Rome II IBS were included in the third 
study (paper III). In the third study, the majority of patients excluded at the first visit had organic 
disease to explain their symptoms of IBS. Patients lost to follow up did not differ with regard to 
the assessed characteristics at baseline. The possibility of selection bias should therefore not 
seriously threaten the validity of our findings.
In the population based survey of IBS, the fact that only 42% of invited subjects were 
included opens up for selection bias. As discussed in paper IV, responders differed with regard to 
age and gender. Since prevalence estimates are more vulnerable for selection bias than measures 
of association, we provided gender and age adjusted estimates for the prevalence of IBS. A study 
of non-responders in the Oslo Health study, which had many similarities with our study with 
regard to design, measurement and response rate (46%), no evidence of major systematic errors 
was found.109 Still, we can not exclude that our study population differs from the population 
frame. This threatens the external validity of our findings as does the fact that inhabitants in 
Oppland might differ from the population of Norway in features associated with IBS. For 
instance, according to national data (www.ssb.no), the average age is higher in Oppland. Since 
IBS is most prevalent in young adults, the overall prevalence of IBS could be higher in Norway 
than what we observed in Oppland county.
Information bias 
Measurement of gastrointestinal symptoms and other characteristics with questionnaires 
completed by patients could introduce information error. Although we used formally validated 
questionnaires to a large extent, this was not the case with the Rome II criteria for IBS. Our use 
of the electronic questionnaire (see paper I and II) made it necessary to perform a modified 
translation, based on the original criteria and the Rome II modular questionnaire.5 Although the 
Rome II modular questionnaire has been developed for clinical investigations, it has not been 
formally validated and we found it of limited value, supported by a recent survey.3 Moreover, we 
used a three month time frame for assessment of symptoms to reduce recall bias, as 
recommended by the Rome II committee. The Rome II criteria demand symptoms present for 
more than three months within the last year to qualify for a diagnosis of IBS. We might therefore 
have underestimated the prevalence of IBS in the population based survey. Concurrently, 
prevalence estimates might have been falsely inflated in this survey since some subjects with 
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Rome II IBS have organic diseases to explain their symptoms. These issues are discussed in paper 
IV.
 We assessed mood disorder with the SCL-10, which performs almost as well as the full 
version (SCL-25, correlation coefficient 0.97).74 However, the literature suggests that only 50-60% 
of the “cases” identified by these instruments qualify for one or more mental disorders in clinical 
interviews.110 Adverse life events were reported by patients in the general practice study. 
Although perhaps indicators of chronic life stress which are important features in IBS, we placed 
little emphasis on these measures since structured interviews of life event stress have been shown 
to be more reliable in this context.31;111;112
 With regard to the comorbidity of IBS, most studies to date have focused on the presence 
of disorders such as fibromyalgia and chronic fatigue syndrome in selected patient groups.41 We 
primarily assessed comorbid symptoms in our studies, which could be less troublesome with 
regard to information error than measurement of diagnosed comorbid disorders. Symptoms of 
fibromyalgia and chronic fatigue syndrome sometimes overlap and different criteria have been 
used which make comparisons difficult.41 Accordingly, the self reported prevalence of 
fibromyalgia in our population based survey should be interpreted with caution. Nevertheless, 
our results would have been strengthened by the use of validated questionnaires for specific 
comorbid symptoms and disorders in IBS.
Confounding
A simple definition of confounding would be the confusion, or mixing, of effects: this definition 
implies that the effect of exposure is mixed together with the effect of another variable, leading 
to bias. In this thesis, we place much emphasis on the confounding effect of comorbidity in IBS. 
Nevertheless, our studies of subjects with IBS and their characteristics are vulnerable for 
confounding effects of other unmeasured factors with possible effects on the reported 
associations. Moreover, cross-sectional studies can at best demonstrate associations. Further 
causal relations must be left to studies with proper designs (e.g. observational analytic designs). In 
paper III and IV the possibility of confounding is discussed. 
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WHAT HAVE WE LEARNED AND WHERE DO WE GO?
I have now spent five years increasing my knowledge about IBS. A major lesson for me is how 
much we do not understand about this disorder. Nevertheless, we have learned that:  
1. IBS afflicts 8% of adults in a Norwegian general population (according to the Rome II 
criteria) with a female predominance and an age dependent decrease in prevalence. In 
such a highly prevalent chronic disorder which leads to consultations with physicians for 
the majority in the long run, optimal diagnosis and treatment should be of high priority. 
2. Abdominal complaints represent a significant workload in general practice, with 15% of 
patients attending their GP reporting abdominal complaints for which they wish to 
consult. FGID are diagnosed in half of these patients and IBS is the most common 
diagnosis made by GPs. In our study, a correct distinction between FGID and organic 
diseases based on characteristics of patients proved difficult. Since patients with FGID 
require different investigations and treatment than patients with organic diseases, this 
distinction is of importance and could be facilitated by identification of the typical 
symptoms of FGID. 
3. GPs are unfamiliar with symptom-based diagnostic criteria for IBS and the agreement in 
the diagnosis of IBS between GPs and Rome II criteria was unexpectedly poor. Since 
most patients with IBS are managed by GPs, the external validity of studies using these 
criteria is questionable. The Rome II criteria, by many considered too strict for clinical 
practice, identified nearly twice as many patients with IBS than did the GPs. This implies 
that GPs lack the detailed knowledge of the typical symptoms of IBS needed to provide a 
confident diagnosis. The validity and applicability of the Rome II criteria in clinical 
practice remains unanswered.  
4. Somatic and psychiatric comorbidity are striking features of IBS with clinical implications. 
The odds for reporting a variety of bodily and psychological symptoms and disorders 
were two to seven times higher in subjects with IBS than in subjects without IBS. 
Importantly, we demonstrate that such comorbidity is a feature of IBS and not only of its 
consulters. Furthermore, our findings challenge the general assumption that IBS is a 
disorder which leads to reduced quality of life, working disability and increased use of 
health care resources. In this context, the comorbidity of IBS is a major confounder 
which should be taken into account in future attempts to measure the severity and impact 
of IBS. The comorbidity of IBS also has implications for aetiology and treatment: 
Structured assessment of somatic comorbidity can identify subgroups of patients with 
predominantly psychological and biological aetiologies in need of targeted treatments. 
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So, where do we go? For those of us engaged in patients with IBS, these are exciting times 
with research at blossom. In particular, research on basic pathophysiological mechanisms in 
the gastrointestinal tract receives great attention. Some experts believe IBS will turn out to 
represent a series of poorly understood organic diseases.13 Others caution against this 
“organification” of IBS and find it unlikely that an altered gene or set of specific biological 
aetiologies will explain a complex brain gut disorder such as IBS.15 Our findings suggest some 
roads to travel to increase our understanding of IBS and to provide better diagnosis and 
treatment for patients with symptoms of IBS.  
Toward a better understanding of IBS? 
The observed comorbidity of IBS and its implications suggests that researchers and 
physicians sometimes need to look beyond the gastrointestinal tract. Moreover, our findings 
highlight the need for further clinical and epidemiological research performed in 
representative samples of subjects with IBS. It could be wise to pay attention to William 
Grant Thompson, a major contributor to current understanding about IBS, who recently 
wrote: One group of internists claim that functional disorders such as IBS are “artefacts of specialisation”. 
They hypothesise that such healthcare seeking patients have somatisation disorders and if they see a 
gastroenterologist they will leave with a diagnosis of IBS or dyspepsia, while a rheumatologist will diagnose 
fibromyalgia, and a neurologist non-specific headache. Many will disagree with this concept, but it should force 
us to think beyond our specialty. It is even tempting to speculate that the majority of those individuals with 
IBS symptoms who shun seeking health care do not consider it a medical problem at all. In 1984, Thomas 
Almy asked: Is the IBS a quantitative or merely qualitative departure from the psychophysiological reactions 
of human beings?” Will the IBS prove to be a disease or a series of diseases for which a structural or 
biochemical defect will be discovered, or are IBS symptoms, like tears, a person’s psychophysiological reaction to 
the environment?113
These observations underline the necessity of maintaining a holistic perspective on IBS in 
research and in clinical encounters. By constantly looking at IBS from different viewpoints 
and by combining basic, clinical and epidemiological research, the future could hold 
considerable promise for our understanding of IBS.114
Can we improve current diagnosis and treatment of patients with IBS? 
In clinical encounters with patients who present with symptoms of IBS, it is our duty as 
physicians to provide diagnosis and treatment based on available evidence. Although we need 
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to understand more about IBS, this should not keep us from implementing current 
knowledge about IBS in clinical practice. A positive symptom based approach is widely 
recommended as the preferred way of diagnosing IBS, but requires that physicians have 
sufficient knowledge about the typical symptoms of IBS. Sufficient knowledge would also 
facilitate reassurance and education which, together with a confident diagnosis, constitute 
cornerstones in the recommended graded general treatment approach. Since this approach is 
considered to be what most patients need, the efficacy of this multidimensional intervention 
should be explored. Evidently, some patients with IBS need specific treatment. I frequently 
encounter referred patients who present with severe IBS for which I have little to offer. Many 
of these patients have excessive comorbidity which further complicates treatment. We need 
to provide these patients with proven effective treatment such as gut focused hypnotherapy. 
Such psychological intervention and emerging drug therapies targeted at end organ 
dysfunction in the gut could prove even more effective if we can identify patients with 
predominantly different aetiologies. Our findings therefore call for research on therapy 
targeted at different levels of the brain gut axis, tailored to the needs of the individual patient 
with IBS.
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APPENDIX
A comment on some commonly used terms and definitions 
IBS; Disease, disorder or illness?
I use the term functional gastrointestinal disorder (FGID) in this thesis, as recommended by the 
Rome committee. However, IBS meets dictionary definitions of disorder, disease and illness in 
English language which probably explains why these terms are used interchangeably in the 
literature. The word disorder is usually applied when function is altered without morphological 
change, often implying unknown or psychological causes, leaving disease for entities with an 
organic cause. Accordingly, the term functional disorder applies to IBS since no organic cause 
has been identified.  Illness is a broader concept that differs from physicians’ biomedical concept 
and embodies a sick person’s experience, so regardless of whether the term disease or disorder is 
used, illness applies from the patient’s perspective.
 In our studies, we translated FGID to “funksjonelle mageplager”. In Norwegian language, 
there is a major difference in labelling IBS plage (disorder), lidelse (illness) or sykdom (disease) at 
least in clinical encounters with patients. To my experience, researchers and physicians in Norway 
do not use the disease term in IBS.
Aetiology, pathogenesis, causes and mechanisms 
I use the term aetiology to describe a variety of factors which together contribute to the 
development (pathogenesis) of IBS. However, the aetiology of IBS is poorly understood and a 
range of causes and mechanisms have been associated with the pathogenesis in IBS (see general 
introduction). More than one factor is necessary to develop IBS, as conceptualised in the 
biopsychosocial model and in line with modern epidemiological concepts where causes of disease 
have both genetic and environmental determinants. 
Comorbidity of IBS, subjective health complaints, somatisation or medically unexplained physical symptoms 
(MUPS)?
I use the term comorbidity to describe co-occuring somatic (=bodily) and psychiatric symptoms 
and disorders/ diseases in subjects with IBS. This term contrasts with the frequently used terms 
“extraintestinal/ non-gastrointestinal symptoms of IBS” because it does not imply that these 
symptoms are aetiologically linked to IBS.  
 We assessed comorbid symptoms in patients with IBS with the Subjective health 
complaints (SHC) inventory (see paper III). The term subjective health complaints describes 
common health problems reported by subjects without making aetiological inferences or linking 
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symptoms to specific diagnoses. The same thinking applies for MUPS, although this term is 
reserved for physical (=somatic) symptoms where no medical explanation can be found.   
 What about somatisation? This term describes a phenomenon with multiple somatic 
symptoms without a plausible explanation by pathological findings. Whereas some infer that 
these symptoms result from psychological distress, others define somatisation as medically 
unexplained physical symptoms (MUPS) without making aetiological inferences. I use the term 
somatisation as a possible explanation of excessive somatic comorbidity in a subset of patients 
with IBS. In this context, somatic symptoms have been proposed to be markers for psychological 
influences on aetiology (see general discussion).
Consultation behaviour in IBS: Subjects with IBS, Consulters/ non-consulters or patients/ non-patients? 
Not all with IBS consult physicians, and those who do might end up seeing their GP or different 
kinds of specialists in secondary and tertiary health care (see general introduction). In research, 
this feature is frequently labelled consultation behaviour or healthcare seeking behaviour. 
Different terms are used to separate subjects with IBS who do not consult (non-consulters, non-
patients) from those who do consult (consulters, patients). In the population based survey, I 
divide subjects with IBS in IBS consulters and IBS non-consulters. In the general practice study, I 
use the term patients with IBS (all had consulted or wished to consult their GP for abdominal 
complaints). 
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Screening questionnaire in the waiting room 
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 Rome II questionnaire for IBS translated to Norwegian 
The questions were similar in the general practice study and in the population based survey of 
IBS. The layout was different in the general practice study, due to the electronic questionnaire. 
1 MAGESMERTER/UBEHAG SISTE TRE MÅNEDER
1.1 Har du vært plaget av smerter eller ubehag i magen i løpet av de siste 
3 måneder? 
Hvis Nei, hopp til spørsmål 2
JaNei
1.2 Har du kjent disse plagene minst 1 dag i uken  
i 3 uker eller mer i løpet av de siste 3 måneder? 
JaNei
1.3 Blir smertene/ubehaget i magen bedre etter at du har hatt avføring? 
JaNei
1.4 Begynner plagene i forbindelse med at du får enten hyppigere eller 
sjeldnere avføring? 
JaNei
1.5 Begynner plagene i forbindelse med at du får enten løsere eller fastere 
avføring? 
JaNei
2 OM FORDØYELSES- OG  TARM-FUNKSJONER
2.1 Hender det at du har mindre enn 3 avføringer pr uke? 
JaNei
2.1.1 Hvis Ja,
De siste 3 måneder, har dette hendt oftere enn hver 4.uke? JaNei
2.2 Hender det at du har hard eller knollet avføring?  
JaNei
2.2.1 Hvis Ja, De siste 3 måneder, har du hatt hard eller knollet avføring oftere 
enn hver 4. gang du er på toalettet? JaNei
2.3. Hender det at du har mer enn 3 avføringer pr. dag? 
JaNei
2.4. Hender det at du har løs (grøtaktig) eller vandig avføring? 
JaNei
2.4.1 Hvis ja: De siste 3 måneder: har avføringen vært løs/grøtaktig eller 
vandig mer enn 3 av 4 ganger (75%) du er på toalettet? JaNei
2.5 Hender det at du har følelsen av ikke å få ut all avføringen når du er på 
toalettet?  
JaNei
2.6 Hender det at du må presse eller trykke for å få avføring? 
JaNei
2.7 Hender det at du må på toalettet med en gang fordi du har problemer med 
å vente med (holde tilbake) avføringen? 
JaNei
2.8 Hender det at du ser slim i avføringen?  
JaNei
2.9 Hender det at du føler deg stinn eller oppblåst (luft) i magen?  
JaNei
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Abdominal complaints in general practice
Diagnoses and characteristics of patients
Per Olav Vandvik1, Pa˚l Kristensen2, Lars Aabakken3 and Per G. Farup1,4
1Department of Medicine, Innlandet Hospital Health Authority, Gjøvik, 2Ranheim Medical Centre, Trondheim,
3Department of Medicine, Rikshospitalet University Hospital, Oslo, 4Unit for Applied Clinical Research, NTNU,
Trondheim, Norway.
Scand J Prim Health Care 2004;22:157/162. ISSN 0281-3432
Objective / The study evaluates the prevalence and diagnoses of
abdominal complaints in general practice, and compares character-
istics and symptoms of patients with functional gastrointestinal
disorders (FGIDs) and organic diseases.
Design / A cross-sectional study.
Setting / Nine centres with 26 participating general practitioners
(GPs) in Norway.
Subjects / 3097 out of 3369 consecutive adult patients answered a
questionnaire regarding abdominal complaints within the last 3
months. Those who consulted for the complaints were eligible for this
study.
Main outcome measures / The GPs’ diagnoses and patients’
characteristics were reported in questionnaires.
Results / 460 out of 1499 patients with abdominal complaints
consulted for these complaints; 392 were included in this study. The
GPs diagnosed a FGID in 167 (42.6%) patients, organic disease in 145
(37.0%), and made no diagnosis in 80 (20.4%). Stress-related
symptoms were a statistically significant predictor of a FGID (OR
1.95) and weight loss predicted in addition organic disease (OR 2.7) in
128 patients with a verified diagnosis.
Conclusion / Abdominal complaints are a common problem in general
practice. The distinction between FGID, which accounted for half of
the diagnoses, and organic disease was difficult. The only significant
predictor for FGID was stress-related symptoms.
Key words: diagnoses, functional gastrointestinal disorders, gastro-
intestinal diseases, general practice.
Per Olav Vandvik, Department of Medicine, Innlandet Hospital
Health Authority, Kyrre Greppsgt. 11, NO-2819 Gjøvik, Norway.
E-mail: per.vandvik@ start.no
Most patients with abdominal complaints are diag-
nosed and treated in general practice, where such
problems account for 7/10% of the consultations
(1,2). At least half of these consultations are for
functional gastrointestinal disorders (FGIDs), such
as irritable bowel syndrome (IBS) and functional
dyspepsia (1,2). Since the FGIDs and the organic
diseases are in large part handled differently, the
GP must consider at an early stage which of them is
most likely. This distinction is important for selection
of further investigations or referral to secondary
care, and for correct treatment. There is little knowl-
edge on how to make this distinction based on
symptoms alone (3,4). It is likely that GPs, who
often are unfamiliar with the use of strict diagnostic
criteria for FGIDs, use other characteristics than
merely the abdominal symptoms to separate FGIDs
and organic disease (1,3). Increased knowledge
about characteristics in patients with FGIDs and
organic diseases could help the GPs to a correct
diagnosis.
This study investigates the prevalence of abdominal
complaints in general practice and the spectrum of
diagnoses made by GPs, and compares characteristics
of patients diagnosed with FGIDs with those diag-
nosed with organic diseases.
MATERIAL AND METHODS
The study was carried out in the county of Oppland,
which comprises 110 000 inhabitants served by 99 GPs
and one hospital. In Norway, patients must seek
medical care through their locally assigned GP. In all
26 GPs, working in 9 (out of 12 invited) general
practices of varying sizes, participated in the study.
Two practices were located in a town with 18 000
inhabitants, 7 were located in the countryside. The
study period was from February to April 2001, during
Most patients with abdominal complaints are
managed by their GP. A correct distinction
between functional disorders and organic dis-
eases is necessary.
. Consultations for abdominal complaints con-
stituted a significant workload for GPs.
. Functional disorders were diagnosed as fre-
quently as organic diseases.
. Patients with functional disorders and organic
diseases displayed apparently similar charac-
teristics, which made this distinction a chal-
lenge for the GP.
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10 days of practice for each participating GP. Mem-
bers of the practice staff were responsible for admin-
istration of questionnaires. GP characteristics such as
age, sex, professional experience, and knowledge of
diagnostic criteria for FGID were recorded.
Consecutive patients aged 18 years or older con-
sulting their GPs were asked to complete a brief
questionnaire in the waiting room. This questionnaire
assessed sex, age, presence of abdominal complaints
within the past 3 months, and consultations for the
complaints. Patients with abdominal complaints who
wished to consult the GP the same day for these
complaints (main or additional problem) were eligible
for the study.
Patients who had given informed consent completed
an additional questionnaire developed by the authors,
regarding certain symptoms and characteristics. This
questionnaire was administered on a palm-top com-
puter. Patients were assisted by practice staff in
completing the questionnaire, if necessary. The sever-
ity of abdominal pain/discomfort was measured as
mild (no interference with daily activities), moderate
(some interference, but not disruption of daily activ-
ities) and severe (with disruption of daily activities)
and frequency of abdominal pain/discomfort as num-
ber of days per week with abdominal pain/ discomfort.
Two questions assessed the patients’ own opinion of
stress and psychological factors as relevant to the
abdominal complaints (‘‘stress-related symptoms’’)
and whether patients feared that the abdominal
complaints could be due to cancer/other serious
disease (‘‘fear of cancer’’).
General practitioners’ diagnosis
The GPs’ diagnosis for the abdominal complaints was
based on all available information about the patient, in
accordance with daily practice. If the abdominal
complaints had been sufficiently evaluated (known
from earlier or evaluated during the current consulta-
tion) the GP reported the diagnosis on the palm-top
computer. The GP had to choose one of three main
categories (functional disorder, organic gastrointest-
inal disease, other disease) and thereafter one option
within the chosen category. Since some of these
diagnoses might have been provisional and therefore
unreliable, the GPs were also asked whether the
diagnosis was considered to be verified (meaning
that, for the FGID, they had no evidence of organic
disease, and for the organic diseases that tests had
confirmed organic disease). The GPs also reported the
number of previous visits for abdominal complaints
during the last two years (0/1/5//5).
Statistics
Differences in characteristics between groups were
evaluated with chi-squared, MannWhitney U, and
Student’s t-tests and 95% confidence intervals (CI)
were calculated if possible. A stepwise forward logistic
regression analysis was performed to predict charac-
teristics of patients with FGID and organic diseases.
All variables with a p-value B/0.20 in univariate
analyses were entered in the model. The statistical
analyses were carried out using SPSS for Windows v.
10.0, and StatXact v. 5.
Ethics
The study was performed according to the Declaration
of Helsinki, and approved by the Regional Committee
for Medical Research Ethics at the University of Oslo,
and the Data Inspectorate, Oslo, Norway.
RESULTS
General practitioners and patients
Of the 26 participating GPs (20 M and 6 F, median age
45 years [range 26/68]), 15 were specialists in general
practice and the median number of years in general
practice was 10 (range 0/20). Three of 26 GPs knew of
diagnostic criteria for FGID, but none applied such
criteria regularly. Fig. 1 shows the flow chart of
patients in the study. Of 460 patients with abdominal
complaints for which they wanted to consult, 392
patients (147 M and 245 F) with mean age 52 years
(SD 17.2, range 18/90) were further characterized in
the electronic questionnaire. Duration of complaints
for more than 1 year was reported by 290 patients
(74%), and 273 (70%) had consulted their GP for
abdominal complaints earlier. In 114 patients (30%)
the abdominal pain/discomfort was mild, in 215
patients (56%) moderate, and 53 patients (14%)
reported severe abdominal pain/discomfort. One hun-
dred and fifty patients (38%) feared that the abdom-
inal complaints could be due to cancer or other serious
disease. There were no significant differences between
men and women regarding these characteristics (data
not shown).
GPs’ diagnoses for the abdominal complaints
The GP reported a diagnosis in 312 patients; 128 had a
diagnosis that was considered by the GP as verified.
The proportion of verified diagnoses was significantly
lower in patients with no previous visits for abdominal
complaints during the last 2 years than in patients with
1 to 5 visits and in patients with more than 5 visits
(25%/47%/52%, p/0.001). Table I shows the diag-
noses in all patients and in those with a verified
diagnosis. No diagnosis of malignant disease was
made by the GPs in this study.
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Comparison of patients with FGID and organic diseases
Table II shows the characteristics of patients (all
patients and the subset with verified diagnoses) with
FGID and organic diseases (both gastrointestinal and
other diseases) and a comparison between the groups
with univariate analyses. By logistic regression, ‘‘stress-
related symptoms’’ predicted a diagnosis of FGID in all
patients (OR 1.95, 95% CI: 1.24/3.1), and ‘‘stress-
related symptoms’’ (OR 2.7, 95%CI: 1.25/5.6) and ‘‘no
weight loss last year’’ (OR 2.7, 95% CI: 1.1/6.7)
predicted FGID in patients with a verified diagnosis.
DISCUSSION
Main findings
In this general practice population, 14% wished to
consult for abdominal complaints during the current
consultation. This suggests a somewhat higher fre-
quency of consultations than reported earlier (1,2).
Although a common reason for consultation, the
complaints seldom disrupted daily activities and a
minority had consulted their GP more than 5 times
during the last 2 years. Importantly, nearly half of the
patients in this study feared that the abdominal
complaints could be due to cancer or other serious
disease. Such fear should be recognized by the GP, as
it may have been the incentive to consult and has
negative impact on the course of the abdominal
complaints (1,4).
The GPs’ diagnoses for the abdominal complaints
represent a wide range of non-malignant disorders and
diseases. Our study adds to the evidence that the
FGIDs constitute a considerable workload for GPs,
with IBS being the most frequent functional disorder
(1,2).
Fig. 1. Flow chart of patients in the study.
Table I. General pactitioners’ diagnoses in all patients, and in
patients with a veriﬁed diagnosis. Results are given as numbers
and whole percentages.
Diagnosis All patients Patients with
a verified
diagnosis
No diagnosis 80 (20%) 0 (0%)
Functional gastrointestinal
disorders
167 (43%) 50 (39%)
Functional reflux 12 (3%) 5 (4%)
Functional dyspepsia 20 (5%) 7 (5%)
IBS 52 (13%) 22 (17%)
Functional diarrhoea 14 (4%) 3 (2%)
Functional constipation 24 (6%) 7 (5%)
Functional bloating 17 (4%) 1 (1%)
Functional abdominal pain 20 (5%) 4 (3%)
Functional other 8 (2%) 1 (1%)
Benign organic gastrointestinal
diseases
109 (28%) 61 (48%)
GERD/oesophagitis 41 (10%) 23 (18%)
Peptic ulcer disease 6 (2%) 5 (4%)
Infectious gastroenteritis 6 (2%) 1 (1%)
Small bowel disease 3 (1%) 2 (2%)
Food allergy/intolerance 2 (1%) 1 (1%)
Liver/biliary/pancreatic disease 9 (2%) 5 (4%)
Inflammatory bowel disease 5 (1%) 3 (2%)
Diverticulosis/diverticulitis 18 (5%) 12 (9%)
Ano-rectal disease 6 (2%) 4 (3%)
Adherences 7 (2%) 4 (3%)
Other gastrointestinal disease 6 (2%) 1 (1%)
Other diseases 36 (9%) 17 (13%)
Drug adverse event 17 (4%) 7 (5%)
Kidney/urinary disease 7 (2%) 4 (3%)
Gynaecologic disease 4 (1%) 3 (2%)
Psychiatric disease (in need of
treatment)
8 (2%) 3 (2%)
Malignancies 0 (0%) 0 (0%)
Total 392 (100%) 128 (100%)
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We found, like others, that the GPs do not know or
use strict symptom-based criteria to diagnose the
FGID (1,3). How then do GPs distinguish between
the FGIDs and organic diseases in daily practice? Our
findings suggest that GPs often trust their clinical
judgement without the need for verification by ex-
tensive tests or referrals, as only half of the diagnoses
were considered verified even in the most frequent
consulters. It is also likely that the GPs use other
factors than merely abdominal symptoms to make a
diagnosis for the complaints. In a general practice
study from the UK, patients with IBS were more often
women, feared cancer more often, attributed their
complaints to stress, and consulted their GP more
often compared with patients with organic disease (1).
In our study, there were no significant differences
between patients with FGID and organic diseases for
these and other characteristics, except for ‘‘stress-
related symptoms’’, which predicted FGID, and
‘‘weight loss last year’’, which predicted organic
disease in those with a verified diagnosis. A recently
published study shows that GPs often believe that
symptoms in the FGID are related to psychological
factors (3). It is also shown that denial of a role of
stress in explaining abdominal symptoms predicts
referral to specialists (1,5). We suggest that the GPs
might use stress-related symptoms in distinguishing
between functional disorders and organic disease.
Whether stress-related symptoms play a greater
role in the FGID than in organic diseases remains
unclear.
Symptoms that may predict organic disease (alarm
symptoms) are considered to be important in the
diagnostic evaluation of patients with abdominal
complaints. Guidelines for FGID define weight loss,
blood in the stools, and nocturnal symptoms as alarm
symptoms, which should lead to further investigations
(6/8). However, the predictive values of alarm symp-
toms in patients with dyspepsia in primary care are
questionable, and the decision on whether and how to
investigate is complex (9,10). In our study, the only
alarm symptom that predicted organic disease was
‘‘weight loss last year’’. This predictor was found only
in those with a verified diagnosis. On the other hand,
we fail to confirm that ‘‘observed blood in the stools’’
predicts organic disease. Two studies have shown that
rectal bleeding is associated with cancer in general
practice (11,12). However, one study of subjects with
IBS found blood in the stools to be frequent and not
associated with organic disease (13). Nocturnal symp-
toms were present in half of the patients, and more
often in patients with FGID than in patients with
organic disease (p/0.07). One study has found
nocturnal awakening to be associated with organic
dyspepsia (14). Milk intolerance, defined as worsening
of abdominal complaints by intake of milk products,
was reported by one-third of the patients, suggesting
lactose malabsorption (LM). However, the clinical
value of detecting LM seems unclear (15/17).
Strengths and limitations
A particular strength of the study is the high
participation rate among the patients (see Fig. 1)
Table II. Characteristics of patients with functional gastrointestinal disorders (FGID) and organic diseases, with differences between
the groups. All values are expressed as percentages, if not otherwise indicated.
Characteristics All patients with GP diagnosis Patients with verified GP diagnosis
FGID
n/167
Organic
n/145
Statistics* FGID
n/50
Organic
n/78
Statistics*
Females 65 62 3 (/7; 14) 73.5 73.1 0.4 (/16; 16)
Age in years (mean/SD) 52.6 (16.4) 53.2 (18) 0.8 (/4.7; 3) 54.1 (15.6) 53.1 (18.6) 0.75 (/5.3; 7.4)
Symptom duration /1 year 76 72 4 (/6; 13) 88 82 6 (/8; 17)
Symptom severity (mild/moderate/severe) 29/55/15 24/62/14 p/0.51 20/67/12 26/62/12 p/0.54
Symptom frequency (0/3/4/5//5 days/week) 57/15/28 56/15/30 p/0.35 59/16/25 55/15/30 p/0.2
Stress-related symptoms 60 43 17 (5; 27) 64 42 22 (5; 39)
Fear of cancer/serious disease 42 37 5 (/6; 16) 36 35 1 (/18; 16)
Visits for complaints last 2 yrs (0/1/5//5) 26/66/8 25/64/11 p/0.51 12/78/10 18/69/13 p/0.73
Alarm symptoms
Weight loss last year 25 32 7 (/3; 17) 18 35 17 (1; 31)
Nocturnal symptoms 60 50 10 (/1; 21) 58 51 7 (/11; 24)
Observed blood in stools 16 18 2 (/6; 11) 18 17 1 (/11; 17)
Colon cancer in first-degree relatives 10 12 2 (/5; 9) 12 9 3 (/8; 17)
Milk-related symptoms 28 30 2 (/9; 12) 30 35 5 (/12; 21)
*Statistics are given as differences between groups with 95% confidence intervals, or with p-values.
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and the design of the study, which allowed the GPs to
perform their practice as usual. This should minimize
the risk for selection bias and ensure that the GPs’
diagnoses are representative of ‘‘real life’’ diagnoses.
However, some limitations need to be considered. The
observed proportion of patients who wished to consult
for abdominal complaints may be an overestimate, as
some of the patients might have been reminded about
minor complaints that they wished to discuss with the
GP in addition to the planned agenda for the
consultation.
Another limitation of our study is the lack of a gold
standard for the diagnosis of FGID and organic
disease. It may be questioned whether the GPs’
diagnoses identify patients with ‘‘true’’ functional
disorders and organic diseases. It is also possible
that organic diseases such as diverticulosis coexist
with FGIDs such as IBS in some patients. Although it
is likely that the FGIDs could have been better
classified with the use of strict criteria, we have no
reason to believe that the distinction between FGIDs
and organic diseases is incorrect.
Since the sample size is limited and the confidence
intervals are wide, clinically significant differences
might have been missed (type II error). However,
there was no trend towards any clinical significant
differences apart from the reported predictors. Our
selection of patient characteristics was limited, and did
not include a thorough characterization of abdominal
symptoms. Guidelines suggest that identification of
the typical abdominal symptoms within the various
FGID syndromes is the key to a correct and confident
diagnosis (6/8,18). We do not know to what extent
GPs use such characteristics in their daily practice,
although we have shown that few use strict criteria.
The lack of predictive value for alarm symptoms
(blood in stools, nocturnal symptoms, milk intoler-
ance) in this study, except weight loss, should be
interpreted with caution. For example, not all organic
diseases are associated with blood in the stools,
nocturnal symptoms, or hereditary factors. It is also
possible that our simple questionnaire is likely to be less
accurate than the detailed assessment of alarm symp-
toms by an experienced doctor. Interestingly, a recent
review on the diagnosis of IBS suggests that alarm
symptoms are suitable for use in questionnaires (19).
Conclusion and implications for future research
Abdominal complaints represent a significant work-
load and a diagnostic challenge in general practice.
The similar characteristics in patients with FGIDs and
organic diseases make this distinction difficult.
Whether the typical symptoms defined by the criteria
for FGID are more helpful in distinguishing patients
with FGIDs from those with organic diseases should
be evaluated.
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Diagnosing Irritable Bowel Syndrome: Poor Agreement Between General
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Vandvik PO, Aabakken L, Farup PG. Diagnosing irritable bowel syndrome: poor agreement between
general practitioners and the Rome II criteria. Scand J Gastroenterol 2004;39:448–453.
Background: The new guidelines for diagnosing irritable bowel syndrome (IBS) in clinical practice
recommend the use of the Rome II criteria. In this study the agreement between general practitioners
(GPs) and the Rome II criteria for diagnosing of IBS and functional bowel disorders (FBD) is examined.
Methods: Consecutive patients in general practice were asked to report on abdominal complaints, for
which they had consulted or wanted to consult a GP. Patients with such complaints completed a
questionnaire based on the Rome II criteria for FBD. After consultations, the GPs reported their
diagnoses on the abdominal complaints. Results: Of 3097 screened patients, 553 patients were diagnosed
by their GP and had complete data in the questionnaire. Of these patients, 107 had IBS according to the
GPs and 209 had IBS according to the Rome II criteria (agreement 58%, kappa 0.01 (CI: 0.06; 0.09)).
Agreement on IBS and FBD in patients without organic disease, without reflux or dyspepsia and in
patients with a verified diagnosis was 45%–58%, with kappa values from 0.02 to 0.13. IBS and FBD
cases were diagnosed by the Rome II criteria more often than by the GPs in all these groups of patients
(P 0.001). In patients with diagnostic discrepancies concerning IBS, ‘stress-related symptoms’ was
predictive of a diagnosis of IBS made by the GPs only (OR 2.17 (CI: 1.1; 4.2)). Conclusions: This study
shows poor agreement in the diagnosis of IBS between GPs and the Rome II criteria. Therefore, current
knowledge about IBS based on strict criteria is not necessarily transferable to patients with IBS in general
practice.
Key words: Diagnosis; general practice; irritable bowel syndrome; Rome II criteria
Per Olav Vandvik, M.D., Dept. of Medicine, Innlandet Hospital Health Authority, Gjøvik, Kyrre
Greppsgt. 11, NO-2819 Gjøvik, Norway (fax. 47 61157439, e-mail. per.vandvik @start.no)
As long as there are no diagnostic tests available,diagnosing irritable bowel syndrome (IBS) will be achallenge for general practitioners (GPs). New
guidelines recommend a positive diagnosis, based on the
presence of typical symptoms, absence of alarm symptoms
and absence of structural and metabolic abnormalities to
explain the symptoms (1–3). By employing symptom-based
criteria, such as the Rome II criteria (3), this diagnostic
strategy could be facilitated. These criteria are used in clinical
studies, and are also recommended for use in clinical practice
(4–6). Nevertheless, the criteria are largely unknown and are
poorly validated in general practice, where most patients are
treated (6–8). If data from research and clinical practice are to
be compared, diagnoses in research and practice must be
comparable or, ideally, identical (6).
The primary aim of this study was to assess the agreement
between the GPs’ diagnosis of IBS and the diagnosis of IBS
according to the Rome II criteria. Furthermore, agreement
was assessed for the diagnosis of functional bowel disorders
(FBD), which is a generic term for IBS, functional diarrhoea,
functional constipation and functional abdominal bloating, to
investigate whether a broader definition of bowel disorders
altered the agreement. Possible explanatory factors in cases of
diagnostic discrepancy for IBS were also explored.
Materials and Methods
General practitioners and patients
The study was carried out in the county of Oppland, which
comprises 110,000 inhabitants served by 99 GPs and one
hospital. In Norway, patients must seek medical care through
their locally assigned GP. The study period was from
February to April 2001, during 10 days of practice for each
participating GP. Different practices were selected to obtain a
variety of GPs, practice types and patient profiles. Members
of the practice staff were responsible for conducting the study,
and were released from other duties and trained to ensure
satisfactory protocol adherence in a busy clinical setting.
Consecutive patients aged 18 years or older consulting their
GPs were asked to report on abdominal complaints, using a
brief paper questionnaire administered in the waiting-room.
Patients with abdominal complaints within the past three
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months for which they either had consulted or wished to
consult the GP were eligible for this study. This selection was
chosen to identify patients who were likely to have had a
diagnosis for the abdominal complaints made by the GP.
These patients were asked for informed consent to participate
in the study.
Patient questionnaires and Rome II diagnosis
Before the consultation, the patients included in the study
answered a detailed questionnaire concerning gastrointestinal
symptoms within the past three months. Questions were based
on the Rome II criteria (Modular Questionnaire) for FBD. The
process of translating the questions into Norwegian included
several revisions by experienced specialists and one general
practitioner. Patients were also characterized regarding
duration (more than one year), severity (mild/moderate/
severe) and frequency (number of days per week) of
abdominal pain/discomfort. Two questions assessed the
relation between abdominal complaints and stress/psycho-
logical factors (‘stress-related symptoms’) and patients’ fear
of cancer or other serious disease. The questionnaire was
administered on a handheld computer (Palm m100), pro-
grammed (Pendragon Forms) to classify diagnoses accord-
ing to the Rome II criteria for FBD. The questions were
presented one by one on the screen, requiring an answer
before the next question was presented. Patients entered their
answers by touching the corresponding buttons on the screen,
assisted by practice staff, if necessary.
General practitioners’ diagnoses
After the consultation, the GPs answered questions
presented in the electronic questionnaire, blinded to the
patients’ answers. If the abdominal complaints had been
sufficiently evaluated, the GPs reported the diagnosis by
choosing one option from a list of clinically relevant diag-
noses within three predefined categories (functional gastro-
intestinal disorder, organic gastrointestinal disease, or other
disease) (Fig. 1).
In order to evaluate the reliability of the diagnoses, the GPs
were asked whether their diagnoses were considered to be
verified or not. The GPs were instructed to interpret ‘verified’
meaning that for the functional gastrointestinal disorders, they
had no evidence of organic disease, and for the organic
diseases, that tests had confirmed organic disease. In addition,
the GPs reported whether the patient was known from earlier
consultations, whether a new visit for abdominal complaints
was scheduled, and the number of visits for abdominal
complaints during the past two years (0/1–5/5).
The GPs were instructed to manage their patients according
to ordinary clinical practice, with no special attention to the
study, and they received no formal information about IBS.
GPs’ age, sex, professional experience and knowledge of
diagnostic criteria were recorded.
Analysis of patient groups
Assessment of agreement was performed in five groups of
patients (Fig. 2). The analysis was primarily carried out in all
patients with complete data in the questionnaire and with a
diagnosis of the abdominal complaints made by their GP
(Group A). To evaluate the reliability of the results in group
A, the same analyses were done in the following selections of
patients: Group B (patients in group A without verified
organic disease, as Rome II criteria demand absence of
organic disease), group C (patients in group A without a GP’s
Fig. 1. General practitioners’ (GPs’) diagnostic options in the electronic questionnaire. The GPs first
selected one of the three main groups, and were then presented with several options within the selected
group, of which only one could be chosen. The picture shows the handheld computer. GI = gastro-
intestinal; IBS = irritable bowel syndrome; IBD = inflammatory bowel disease; GERD = gastroesopha-
geal reflux disease.
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diagnosis of heartburn or dyspepsia, as heartburn and
dyspepsia often occur together with IBS and the GPs were
only allowed to choose one diagnosis), group D (patients who
consulted the GP for abdominal complaints the same day) and
group E (patients in group D with a verified diagnosis).
In order to examine possible explanatory factors in cases of
diagnostic discrepancy, two groups of patients within group A
were compared: patients with IBS according to the GP but not
according to the Rome II criteria (‘GP IBS only’) and patients
with IBS according to the Rome II criteria but not according
to the GP (‘Rome II IBS only’).
Statistics
Agreement was assessed using kappa statistics. Differences
between- and within groups were evaluated with the chi-
squared test, the Mann-Whitney U test and the MacNemar
tests. Multivariance analysis was done using stepwise logistic
regression to identify the characteristics of patients with
Fig. 2. Flow chart of patients in the study, with the groups of patients selected for agreement analysis
shown in boxes (groups A–E).
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diagnostic discrepancies concerning IBS. P-values of less
than 0.05 were regarded as statistically significant and 95%
confidence intervals (CI) were calculated. Statistical analyses
were carried out using SPSS for Windows v. 10 and
StatXact v. 5.
Ethics
The study was conducted according to the Declaration of
Helsinki, and approved by the Regional Committee for
Medical Research Ethics in Oslo, and the Data Inspectorate,
Oslo, Norway.
Results
General practitioners
Out of 12 invited general practices, 9 participated in this
study, each with 2 to 5 GPs. Owing to insufficient capacity,
three practices and five GPs did not participate. Three centres
were located in a town with 18,000 inhabitants, and six were
located in the countryside.
Twenty-six GPs (20 M and 6 F) median age 45 years (range
26–68) participated in the study. The GPs reported a median
number of 16 years in general practice (range 0–38) and a
median of 10 years in the current practice (range 0–20) and 15
were specialists in general practice. Twenty-three GPs had
never heard of diagnostic criteria for IBS. Three GPs had
heard of, but did not use, such criteria. None reported a special
interest in gastroenterology.
Patients
Of 3369 consecutive patients, 3097 (92%) answered the
first questionnaire in the waiting-room. The flow of patients
screened for abdominal complaints and the number of patients
included in the groups analysed for agreement are itemized in
Fig. 2. Characteristics of the 553 patients in group A are
presented in Table I.
Agreement between general practitioners and the Rome II
criteria
Tables II and III show the number of patients with diag-
noses of IBS and FBD in group A, and the agreement between
the GPs and the Rome II criteria. Agreement for IBS and FBD
in groups B–E ranged from 45% to 58%, with kappa values
from 0.02 to 0.13. These kappa values did not differ
significantly from zero (data not shown), except for the diag-
nosis of FBD in group B (kappa 0.12 (95% CI: 0.003; 0.13)).
In all groups, IBS was diagnosed significantly more often
(P 0.001) by the Rome II criteria than by the GPs (data
shown only for group A in Table II).
In group A, 167 patients had ‘Rome II IBS only’. In these
patients, the GPs diagnosed other functional disorders,
organic gastrointestinal diseases and other diseases in 78
(46.7%), 68 (40.7%) and 21 (12.6%) patients, respectively.
Table I. Characteristics of all patients with complete data in the questionnaire and a diagnosis made by the general practitioner (GP) (group
A), and in patients with ‘Rome II IBS only’ and ‘GP IBS only’, with a comparison between the last two groups. The results are given as
percentages, if not otherwise indicated
Patient characteristics All patients (Group A) ‘Rome II IBS only’ ‘GP IBS only’ Statistics
No. of patients 553 167 65
Mean age (years) 51.6 52.2 46.8 P = 0.03
Females 65 65 77 n.s. (P = 0.07)
Duration of abdominal complaints 1 year 79 80 83 n.s. (P = 0.20)
Abdominal pain/discomfort severity (mild/moderate/severe) 31/56/12 30/54/16 26/68/6 ns (P = 0.67)
Abdominal pain/discomfort frequency (0–3/4–5/5 days) 64/15/21 58/15/27 66/14/15 P = 0.03
Stress-related symptoms 54 56 74 P = 0.014
Fear of cancer/serious disease 32 35 34 ns (P = 0.92)
Verified diagnosis 50 47 52 ns (P = 0.53)
Patient known by GP 94 95 95 ns (P = 0.81)
New consultation for abdominal complaints scheduled 29 33 19 P = 0.03
Visits for abdominal complaints last 2 years (0/1–5/5) 25/66/8 25/61/14 20/70/9 ns (P = 0.90)
Table III. Number of patients with a diagnosis of FBD, according to
the Rome II criteria and according to the general practitioners, in
group A. The agreement was 49% (kappa 0.05 (95% CI: 0.003;
0.13))
General practitioner FBD
Yes No Total
Rome II FBD Yes 136 225 361
No 56 136 192
Total 192 361 553
FBD = functional bowel disorder.
Table II. Number of patients with a diagnosis of IBS, according to
the Rome II criteria and according to the general practitioners, in
group A. The agreement for IBS was 58% (kappa 0.01 (95% CI:
0.06; 0.09))
General practitioner IBS
Yes No Total
Rome II IBS Yes 42 167 209
No 65 279 344
Total 107 446 553
IBS = irritable bowel syndrome.
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Explanatory factors in patients with diagnostic discrepancies
Differences between groups of patients within group A
with diagnostic discrepancies concerning IBS (‘GP IBS only’
and ‘Rome II IBS only’) are listed in Table I. By logistic
regression analysis, ‘stress-related symptoms’ (OR 2.17 (95%
CI: 1.12; 4.2)) and low frequency of symptoms (OR 1.32
(95% CI: 1.01; 1.72)) were the only significant predictors of a
diagnosis of IBS only, according to the GPs.
Discussion
Principal findings
To our knowledge, this is the first study in which diagnosis
of IBS according to GPs and to the Rome II criteria is
compared. The main finding is the poor agreement between
the GPs’ diagnosis of IBS and the diagnosis of IBS according
to the Rome II criteria, with kappa values reflecting agree-
ment by chance. This finding implies that GPs do not identify
the same group of patients as the criteria do. As most current
knowledge about IBS, such as proven efficacy of novel
therapies, is based upon patients fulfilling such criteria, this
knowledge cannot necessarily be transferred to general
practice where most patients are diagnosed and treated. The
fact that agreement remained poor for the wider diagnosis of
FBD in this study supports our finding of poor agreement for
IBS but was unexpected. In a British study, the GPs diagnosed
IBS in 58% of patients who merited it (according to the Rome
criteria and a consensus expert opinion), but a further 22%
were given a functional label, so 80% were correctly called
functional (9). We therefore expected agreement to increase
for a broader definition of IBS, as the British investigators
suggested that specific diagnostic labels were of little
importance to the GPs.
Another noteworthy finding is that the Rome II criteria
diagnosed IBS approximately twice as often as the GPs. This
is in conflict with a recent report suggesting that these criteria
are too restrictive for clinical practice (10). It is likely that
more patients with IBS will be identified if GPs increase their
knowledge about the typical symptoms of IBS.
The poor agreement observed in this study raises the
question of how GPs diagnose IBS. In our study, few GPs had
heard of diagnostic criteria and none applied such regularly,
which is in harmony with earlier findings (7, 8). The fact that
‘stress-related symptoms’ were reported more often in
patients with ‘GP IBS only’ than in patients with ‘Rome II
IBS only’, suggests that GPs use other characteristics than
merely abdominal symptoms in the diagnostic evaluation.
This is in accordance with results from a study of British
general practice (9). In the same study it was found that a
major predictor of specialist referral was that the patient
denied the role of stress in their symptoms. We postulate that
GPs will more readily conclude with a functional diagnosis in
patients reporting stress-related symptoms, since the patients
will more readily accept the diagnosis. Patients with ‘Rome II
IBS only’ reported more frequent abdominal pain/discomfort
than patients with ‘GP IBS only’. This is probably due to the
definition of IBS in the Rome II criteria, which requires that
symptoms are present, at least every fourth week.
Strengths and weaknesses
Owing to the high response rate (92%), the patients in this
study should be representative of the real population in
general practice. The study design, which allowed GPs to
practice ‘business as usual’, was carefully chosen to ensure
that the GPs’ diagnoses reflected diagnoses given to patients
in this clinical setting. The reliability of the GPs’ diagnoses is
further supported by the fact that nearly all patients included
in the agreement analysis were already known by their locally
assigned GP. This should also minimize the risk of missing
known organic disease.
However, some methodological limitations should be
considered. First, symptom questions were translated from
the published Rome II criteria (Modular Questionnaire) and
applied in electronic questionnaires. The translated Norwe-
gian version of the questionnaire was not formally validated,
and no such versions are available in Norway. The Rome II
questionnaires are developed for clinical investigation and
clinical practice, but a recent publication states that ‘Rome
criteria and questionnaires remain works in progress’ (11).
Regarding the use of electronic questionnaires, handheld
computers are well accepted by patients, with good data
quality and reliability, in various clinical settings (12). We
therefore believe our electronic questionnaires provided good
data on bowel symptoms and correct classification of Rome II
diagnoses. Second, the Rome II criteria require absence of
structural or metabolic abnormalities to explain the symp-
toms. The computerized Rome II criteria did not include a
clinical judgement, which possibly could have influenced
diagnosis. Still, agreement did not improve to reach satisfac-
tory values when patients with verified organic disease (group
B) were excluded from the analysis. Third, the GP was only
allowed to choose one diagnosis for the complaints. Surely
patients may have multiple abdominal symptoms at the same
time; for instance both heartburn- and IBS symptoms, and
they probably present the currently most bothersome symp-
toms to the GP. Agreement did not, however, improve when
we excluded patients with a GP diagnosis of dyspepsia or
heartburn (group C) from the analysis. Fourth, if the GP
suggested a diagnosis for the complaints based only on earlier
knowledge of the patient, he or she may have chosen a
diagnostic option representing symptoms not reported by the
patient at the time of consultation, due to the fluctuating
course of functional gastrointestinal disorders. The fact that
agreement remained unchanged in patients consulting the GP
for abdominal complaints the same day (group D), does not
indicate that this has confounded our results.
Implications for clinical practice and future research
Our findings have important clinical implications as they
question the use of diagnostic criteria for IBS in general
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practice. In both epidemiological and clinical research,
diagnostic criteria are clearly necessary to ensure homogene-
ity in study populations. In clinical practice, a positive
symptom-based diagnosis of IBS may increase both the
patients’ and the GPs’ confidence in the diagnosis, reduce
anxiety about cancer and reduce the need for costly and
potentially harmful tests (4, 9). However, whether diagnostic
criteria are a necessary tool to make such a positive diagnosis
in general practice, and which diagnostic criteria perform
best, remains unanswered. One study of the Rome criteria has
shown high predictive values for IBS, in the absence of red
flags (13). This finding is, however, based on selected
patients. It has been suggested that the Rome II criteria may
be unnecessarily complicated for clinical practice. A Swedish
group has shown that simpler criteria show satisfactory
agreement with the Rome criteria (14). Saito et al. have
demonstrated good agreement between all commonly used
definitions of IBS (Manning, Rome I and Rome II) but it
remains unclear which study definition is the ‘best for clinical
use’ (15). If the criteria are applied in time-consuming ques-
tionnaires, it is also possible that attention may be drawn
away from the clinical encounter and they may represent an
obstacle for successful doctor–patient interaction. Another
issue of interest is whether characteristics that occur fre-
quently in patients with IBS, such as psychosocial problems
and non-gastrointestinal symptoms, should be implemented in
future diagnostic criteria for IBS. Such characteristics could,
for instance, be added in the additional criteria cumulatively
to support the diagnosis of IBS. More research is needed to
clarify this issue. We conclude that IBS remains a diagnostic
challenge for the GP, and that the role of the Rome II criteria
is unclear in this clinical setting. Given the potential benefits
of a positive, symptom-based diagnostic strategy, future
research should address the applicability and validity of
diagnostic criteria for IBS in general practice.
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SUMMARY
Background: Somatic comorbid symptoms might iden-
tify irritable bowel syndrome patients with different
aetiologies and needs of treatment.
Aims: To measure comorbid symptoms in patients with
irritable bowel syndrome in general practice, and to
explore characteristics of patients with low, intermedi-
ate and high somatic comorbidity.
Methods: Prospective study of 208 of 278 consecutive
patients with irritable bowel syndrome (Rome II) in nine
general practices. Questionnaires assessed 22 comorbid
symptoms (subjective health complaint inventory),
psychosocial factors including psychological distress
(Symptom Check list-10) and quality of life (Short
form-12). Subjective health complaint data from 1240
adults (controls) constituted a reference material.
Patients with low, intermediate and high somatic
comorbidity were identiﬁed by a somatic comorbidity
score (17 subjective health complaint items). Health
care seeking was assessed after 6–9 months.
Results: Patients with irritable bowel syndrome (67%
females, mean age 50, s.d. 16) reported 20 of 22
comorbid symptoms signiﬁcantly more frequent than
controls (odds ratios ¼ 2–7, P < 0.001). The somatic
comorbidity score correlated with psychological distress
(R ¼ 0.46, P < 0.001). Patients with high somatic
comorbidity reported higher levels of mood disorder,
health anxiety, neuroticism, adverse life events and
reduced quality of life and increased health care seeking
when compared to those with low and intermediate
somatic comorbidity (P-values < 0.05).
Conclusions: Our ﬁndings support the hypothesis that
structured assessment of comorbid somatic symptoms
might identify subgroups with different aetiology and
needs of treatment.
INTRODUCTION
Most patients with irritable bowel syndrome (IBS) are
cared for by their general practitioner (GP), but most
knowledge about this prevalent and poorly understood
disorder of the brain-gut axis remains to be based on a
small subset of referred patients.1 An intriguing feature
of IBS is the frequent comorbidity with other disorders
and symptoms, which questions whether IBS represents
a speciﬁc diagnostic entity or a part of a functional
somatic syndrome.2–4 A recent systematic review of the
comorbidity of IBS concludes that IBS most likely is a
distinct disorder.5 The authors propose a dual-aetiology
hypothesis to explain the comorbidity of IBS. The
excessive somatic symptoms are markers for somatiza-
tion and identify a subgroup of patients with a
predominantly psychological IBS aetiology, whereas
patients with no comorbid conditions and few general
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physical complaints are more likely to have a predom-
inantly biological IBS aetiology. If this hypothesis is
supported by research, it would help to explain why
both biological markers in the gut, such as visceral
hypersensitivity or motility disturbances, are absent in
one half of patients evaluated, and why most efforts to
treat IBS, whether pharmacological or psychological,
beneﬁt only a subset of patients. The clinical implication
of the hypothesis is that these two groups need to be
identiﬁed, because they are likely to respond to different
treatment strategies. We are not aware of any studies,
which have tested this hypothesis in a general practice
setting.
Our study was undertaken to explore characteristics,
and in particular to measure comorbid symptoms, in
patients with IBS in general practice. Secondly, we
aimed to answer the following research question: Do
patients with low, intermediate and high levels of
somatic comorbidity (SC) constitute subgroups with
different characteristics, natural course of symptoms
and health care seeking (HCS) behaviour?
MATERIAL AND METHODS
Study design and material
This observational, prospective multicentre study was
designed to identify and follow-up a representative
sample of patients with IBS in Norwegian general
practice. The study was carried out during 2001 in nine
practices of different sizes in the county of Oppland,
during 10 days of practice for each participating GP.
Twenty-six GPs (20 males and six females) median age
45 years (range: 26–68) participated in the study. The
GPs were instructed to manage their patients according
to ordinary clinical practice. In Norway, patients must
seek health care through their locally assigned GP.
Members of the practice staff performed the practical
work related to the study.
Consecutive adults aged 18 years or older consulting
their GPs, were asked to report on abdominal com-
plaints, using a brief paper questionnaire administered
in the waiting room. Those with abdominal complaints
within the past 3 months, for which they either had
consulted or wished to consult the GP, were diagnosed
according to the Rome II criteria for functional gastro-
intestinal disorders (FGID). This sampling procedure
was chosen to identify patients with IBS (Rome II), as
opposed to non-patients with IBS (those without a need
to consult their GP). Patients with IBS were invited to
participate in the present study, if the GP had no
knowledge of organic disease to explain their abdominal
complaints. See Figure 1 for ﬂow chart of patients. A
thorough characterization of patients with IBS, with
emphasis on comorbid symptoms, was accomplished by
self-administered questionnaires completed at the ﬁrst
visit. After 6–9 months, included patients were followed
up with an interview.
Questionnaires at the ﬁrst visit
Sociodemographic variables, such as 12 different
adverse life events within the past 6 months and
present employment status were reported in a separate
questionnaire.
Gastrointestinal (GI) symptoms within the past
3 months were assessed in an electronic touch-screen
questionnaire. Questions were based on the Rome II
criteria for IBS, functional dyspepsia and functional
heartburn (modiﬁed Rome II modular questionnaire),
translated to Norwegian by the authors.6 The duration
(number of years), severity (mild, moderate and severe)
and frequency (average number of days per week with
symptoms) of abdominal pain/discomfort was recorded
and an intensity score was calculated by multiplying the
severity with the frequency (range: 0–12). Patients
were asked whether stress and psychological worsened
the abdominal complaints (‘stress-related symptoms’)
and whether they feared that the abdominal complaints
could be due to cancer/other serious disease (‘fear of
cancer’).
Coexisting somatic and psychological symptoms and
quality of life (QoL) were measured by standardized
and validated questionnaires. Twenty-two somatic and
psychological symptoms were assessed by the subject-
ive health complaint (SHC) inventory, which consists
of 29 common health complaints experienced the last
30 days.7 Seven items of GI symptoms were excluded.
The intensity of each symptom in the SHC is graded
on a 4-point scale (not at all/little/some/severe).
Psychological distress was measured by a 10-item
version of the Hopkins Symptom Check list (SCL-10)
with the intensity of each symptom graded from ‘not
at all’ to ‘extremely’. The average item score is often
used as a measure of psychological distress, with a cut
off point of 1.85 recommended as a valid predictor of
mood disorder (anxiety/depression).8 Health anxiety
was measured with the Whitely index which consists
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of 14 questions, with the intensity of each symptom
graded from ‘not at all’ to ‘a great deal’.9 The
personality trait neuroticism was measured by the
Eysenck Personality Questionnaire (EPQ-10).10 Health-
related quality of life (HRQoL) was measured by Short
form-12 (SF-12), with summary physical (PCS) and
mental (MCS) component scores.11
Follow-up interview and measures of outcome
The patients were invited after 6–9 months to an
interview with a member of the practice staff. GI
symptoms were again reported in the electronic ques-
tionnaire. The natural course of IBS was measured as
the presence or absence of abdominal pain/discomfort
and the abdominal pain/discomfort intensity score
within the last 3 months of the follow-up period.
Health care seeking, both related to IBS and for all
causes, was measured as the number of visits to the GP
(by examination of the computerized records) and
alternative health care providers (by patients recall)
during the last 6 months of the follow-up period.
Data analysis
Reference material for comorbid symptoms. The 22 non-GI
symptoms assessed in patients with IBS by the SHC were
compared with reference values from a Norwegian
normal population, consisting of 1240 adults (53%
females, mean age 41 years) included in a cross-
sectional survey in Norway during 1996.12
Comparison of patients with different levels of somatic
comorbidity. The dual-aetiology hypothesis predicts that
the absolute prevalence of comorbid symptoms are
greater in IBS than in a normal population because of
ampliﬁcation processes, that the SC is correlated to
psychological distress, that patients with predominantly
biological or psychological aetiology can be reliably
identiﬁed by counting comorbid symptoms and that a
group of patients will display intermediate SC.
A SC score was created by adding the scores of
17-items in the SHC. Seven items of GI symptoms and
5-items associated with psychological distress (sleep
problems, tiredness, dizziness, anxiety and depression)
were excluded. We hypothesized that dividing patients
with IBS into three groups with low, intermediate and
high levels of SC would increase the chance of
identifying those with a predominantly biological and
psychological aetiology, in each end of the comorbid-
ity spectrum. The reference population mean score
was used to distinguish between low and intermediate
comorbidity, the reference population mean ± 2 s.d. to
distinguish between intermediate and high comorbid-
ity. These three groups of patients were compared for
the assessed characteristics at the ﬁrst visit, and for
HCS and the natural course of IBS in the follow-up
period.
Consecutive patients
3369
→ 2539–Unwilling (277), no
abdominal complaints (1593)
abdominal complaints without need 
to consult a GP (669)
Abdominal complaints last 3 months with
             need to consult their GP
                               830
↓ → 97–Unwilling or unable to answer
questionnaire
Diagnosed according to Rome II criteria
733
↓ → 455- Non-Rome II IBS
Patients with Rome II IBS
278
↓ → 70–Known organic gi-disease,
patient unable or unwilling to 
participate
Patients included in this study
208
↓ → 42–Unwilling, no contact, organic 
disease diagnosed 
 Patients included at follow-up
166
Figure 1. Flow chart of the patients in the
study. GP, General Practitioner; IBS, irrit-
able bowel syndrome.
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Statistics. Comparisons between groups were analysed
with chi-squared, Mann–Whitney U-, Student’s t-tests
and one-way anova. A paired sample t-test was applied
to analyse change of abdominal pain/discomfort inten-
sity in the follow-up period. The association between SC
(17-items in the SHC) and psychological distress (SCL-
10) was assessed by correlation analysis (Pearson r).
Chi-squared tests were performed to determine whether
the observed differences in the SHC-items between
patients with IBS and the reference population were
effects of female gender. All statistical analyses were
carried out with spss for Windows 11.0.
Ethics
The study was performed according to the Declaration
of Helsinki, and approved by the Regional committee for
Medical Research Ethics at the University of Oslo, and
the Data Inspectorate, Oslo, Norway.
RESULTS
Characteristics of patients with IBS
Table 1 gives the characteristics of the 208 included
patients. The 70 patients with IBS not included
(Figure 1) did not differ signiﬁcantly from patients
included in the study with regard to gender, age or GI
symptom characteristics (data not shown). In the 208
patients with IBS, 117 (56%) consulted for abdominal
complaints during the current consultation and
154 (74%) had consulted for such complaints earlier.
No signiﬁcant gender differences were found for the
assessed characteristics, with the exception of age
[53.8 years (s.d. 15.4) in males and 48.6 years (s.d.
16) in females, P ¼ 0.03].
Table 2 shows that there were signiﬁcant differences
between patients with IBS and the reference population
for all comorbid symptoms, except eczema and colds,
ﬂu. In the gender-adjusted analysis of comorbidity in
patients with IBS and in the reference population, all the
observed differences in the individual symptoms
remained statistically highly signiﬁcant (P < 0.001,
data not shown).
Natural course of symptoms and use of health resources
After 6–9 months, 172 of 208 patients (83%) comple-
ted the follow-up interview, of whom six were excluded
because they had been diagnosed with organic GI
disease by the GP during the follow-up period. The
36 patients lost to follow-up did not differ signiﬁcantly
from patients included at follow-up for any of the
baseline characteristics (data not shown). In the 166
patients, 145 patients (87%) reported abdominal pain/
discomfort within the last 3 months. The intensity of
abdominal pain/discomfort was signiﬁcantly lower at
follow-up (mean 3.6, s.d. 3.1) than at the ﬁrst visit
(mean 4.4, s.d. 3.2) (P < 0.001). Thirty-two patients
(20%) had consulted their GP, and 11 patients (7%) had
consulted alternative health care providers, for abdom-
inal complaints. The overall numbers of visits to GPs
was 3.7 (s.d. 2.9, range: 0–14) and to alternative health
care providers 1.9 (s.d.: 0.6, range: 1–9), respectively.
Application of the dual aetiology hypothesis: patients with
low, intermediate and high comorbidity
As predicted in the dual aetiology hypothesis, the SC
score was signiﬁcantly higher in patients with IBS
(mean 13.0, s.d. 8.1) than in the reference population
(mean 5.8, s.d. 5.1) (P < 0.001), showed a signiﬁcant
correlation with psychological distress (R ¼ 0.46,
r2 ¼ 0.22, P < 0.001) and displayed normal distribu-
tions in both groups.
Table 1. Characteristics of patients with IBS, reported at the ﬁrst
visit
Variable
Patients with
IBS (n ¼ 208)
Age (mean/s.d.) 50.3 (16)
Female gender (%) 67
Rome II heartburn (%) 40
Rome II dyspepsia (%) 10
Duration complaints (> 1 year, %) 79
Duration in years (median) 10 (range: 1–55)
APD-severity (mild/moderate/severe, %) 32/55/13
APD-frequency (0–3/4–5/> 5, %) 65/15/20
APD-intensity score (mean/s.d.) 4.4 (3.1)
IBS visits past 2 years (0/1–5/> 5, %) 39/52/7
Stress-related symptoms (yes/no, %) 56
Fear of cancer/serious disease (yes/no, %) 34
Mood disorder (SCL-10 score > 1.85, %) 38
Health anxiety (Whitely) (mean/s.d.) 25.9 (8.5)
Neuroticism (EPQ-10) (mean/s.d.) 4.1 (3)
Two or more of adverse life events (%) 31
Disability pension (%) 17
Quality of life-mental (mean/s.d.) 44.8 (11.7)
Quality of life-physical (mean/s.d.) 38.8 (11.6)
APD, abdominal pain/discomfort; IBS, irritable bowel syndrome; SCL,
Symptom Check list; EPQ, Eysenck Personality Questionnaire.
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Table 3 gives the characteristics differences between
patients with low (score £ 6), intermediate (score 7–16)
and high SC (score >16).
At follow-up, patients with high SC reported higher
intensity of abdominal pain/discomfort than patients
with intermediate or low comorbidity, with mean scores
of 4.4, 3.3 and 2.8 respectively (P ¼ 0.02). Patients
with high comorbidity had also visited their GP more
frequently than those with intermediate or low comor-
bidity, with mean number of visits 4.4, 3.6 and 3.1,
respectively (P ¼ 0.03). No signiﬁcant differences
between these groups of patients were found for GP
visits related to IBS or for visits to alternative health
care providers.
DISCUSSION
This study clearly demonstrates that somatic comorbid
symptoms are common features in patients with IBS in
general practice. Although common in the population
at whole, the odds for reporting 20 of 22 somatic and
psychological symptoms were two to seven times higher
in patients with IBS, with similar results for complaints
of substantial intensity. Likewise, other GI symptoms
such as heartburn or dyspepsia were also reported by a
substantial proportion of patients with IBS. These
ﬁndings harmonize well with two other studies from
general practice,13, 14 and suggest that comorbid
symptoms are as frequent in patients with IBS in
general practice as they are in referred patients.5 The
estimated 38% prevalence of mood disorder is consid-
erably higher than the prevalence of 11% in a
Norwegian population and implies that levels of mood
disorder in patients with IBS in general practice lie
somewhere in between that observed in individuals with
IBS who do not consult and in referred patients with
IBS.8, 15 The observed levels of health anxiety and
neuroticism are also likely to be higher than in a
population without IBS, although we have no control
group in our study to conﬁrm these differences.16
Symptoms of IBS were in most patients, regardless of
gender, of mild-to-moderate intensity, long-standing
Table 2. Percentage of any comorbid
symptoms (score 1 or more) and of sub-
stantial comorbid symptoms (score 2 or
more) in patients with IBS and in a
Norwegian reference population (normals)
Variable
Patients with
IBS (n ¼ 208)
Normals
(n ¼ 1240)
Statistics (OR with 95% CI) IBS
vs. normals
Any Substantial Any Substantial Any Substantial
Headache 76 40 51 20 3.1 (2.2–4.3) 2.7 (2.0–3.8)
Neck pain 73 49 38 19 4.5 (3.2–6.3) 4.2 (3.1–5.7)
Upper back pain 50 32 18 10 4.5 (3.3–6.1) 4.2 (3.0–6.0)
Low back pain 71 43 40 19 3.7 (2.7–5.1) 3.2 (2.4–4.4)
Arm pain 60 34 23 12 4.8 (3.5–6.6) 3.8 (2.7–5.3)
Shoulder pain 69 43 38 20 3.6 (2.6–5.0) 3 (2.2–4.2)
Migraine 17 9 8 5 2.6 (1.7–3.9) 2 (1.2–3.5)
Leg pain 48 22 22 10 3.3 (2.4–4.6) 2.5 (1.7–3.8)
Palpitation 40 19 13 5 4.3 (3.1–6.0) 4.6 (2.9–7.2)
Hot ﬂushes 39 20 9 3 6.9 (4.8–9.8) 8.3 (5.1–13.6)
Sleep problems 63 33 28 11 4.4 (3.2–6.0) 4 (2.8–5.7)
Tiredness 81 45 51 22 4.2 (2.9–6.1) 2.9 (2.1–3.9)
Dizziness 60 22 17 5 7.1 (5.1–9.7) 5.2 (3.4–7.9)
Anxiety 40 19 10 3 6 (4.2–8.5) 6.5 (4.0–10.6)
Depression 55 22 25 9 3.8 (2.8–5.1) 3 (2.1–4.5)
Asthma 20 12 5 3 4.9 (3.1–7.6) 5.3 (3.0–9.4)
Breathing
difﬁculties
39 15 8 3 7 (5.0–10.2) 5.5 (3.2–9.2)
Eczema 18 7 14 5 1.4 (0.9–2.1) 1.4 (0.8–2.5)
Allergies 28 19 12 5 2.9 (2.0–4.2) 4.5 (2.9–7.1)
Chest pain 38 12 13 4 4.2 (3.0–6.0) 3.4 (2.0–5.9)
Colds, ﬂu 45 24 49 23 0.8 (0.6–1.1) 1.02 (0.7–1.5)
Cough 37 19 23 8 1.9 (1.4–2.7) 2.5 (1.7–3.9)
IBS, irritable bowel syndrome; OR, odds ratio; CI, conﬁdence interval.
All differences (both for any and substantial complaints) are statistically signiﬁcant
(P < 0.001) with the exception of eczema and colds, ﬂu.
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and remarkably stable, with only a small proportion of
patients frequently seeking health care for abdominal
complaints. These data add to the evidence that IBS is
less of a problem for patients handled in general
practice than in those referred to specialists, although
symptoms are likely to persist in the majority of
patients.14, 17, 18
Implications of the observed comorbidity and application
of the dual-aetiology hypothesis
It may be questioned whether the excessive comor-
bidity observed in this study is in accordance with
current understanding of IBS and of importance for
the clinical handling of patients. Both somatic and
psychiatric comorbidity are well known clinical fea-
tures of patients with IBS which are associated with
increased use of health resources and a poor out-
come.17, 19–21 GPs recognize patients with IBS to be
polysymptomatic and it has been suggested that non-
colonic symptoms could result in a more accurate
diagnosis of IBS.17, 22 However, although guidelines
for IBS recommend a general therapeutic approach,
they place little emphasis on comorbid somatic
symptoms.15, 23 We postulate that approaching only
symptoms of IBS, whether it be by a well performed
consultation or by novel drug therapies, will not
ameliorate overall suffering or use of health resources
in all patients with IBS.24
The clinically signiﬁcant differences in characteristics
between patients with low and high SC suggest that
subgroups of patients with different aetiologies and
treatment needs do exist, and that they are possible to
identify. However, the observed continuum of comorbid
symptoms demonstrates clouds of patients with consid-
erable overlapping, more than distinct subgroups with
different aetiologies. Accordingly, with our deﬁned cut
off levels, most patients reported intermediate levels of
SC. We agree that the hypothesis is an oversimpliﬁca-
tion, and that the aetiology in many patients is likely to
be explained by interaction of psychological and
physiological factors.5
With these limitations in mind, patients with IBS and
excessive somatic symptoms (high comorbidity) repre-
sent a subset of patients with high levels of psycholo-
gical distress, neuroticism and adverse life events as well
Table 3. Characteristics of patients with
IBS and low, intermediate and high somatic
comorbidity
Variable
Low
comorbidity
Intermediate
comorbidity
High
comorbidity P-values*
Number 42 100 61
Age (mean/s.d.) 51 (16.6) 49 (17.0) 51 (13.7) 0.81
Female gender (%) 57 69 72 0.27
Duration IBS (>1 year, %) 62 84 84 0.01
Rome II heartburn (%) 29 37 53 0.01
Rome II dyspepsia (%) 20 7 8 0.07
APD-intensity score
(mean/s.d.)
4 (3.6) 4.2 (2.6) 5 (3.4) 0.23
Stress-related symptoms (%) 33 61 66 0.007
Fear of cancer (%) 33 35 34 0.99
Health anxiety
(Whitely, mean/s.d.)
22.5 (6.0) 24 (7.3) 31.6 (9.2) < 0.001
Mood disorder (SCL-10, %) 13 32 63 < 0.001
Neuroticism
(EPQ-10, mean/s.d.)
2.5 (2.3) 3.9 (2.9) 5.7 (2.8) < 0.001
Two or more adverse
life events (%)
11 33 51 < 0.001
Disability pension (%) 10 10 34 < 0.001
Quality of life-mental
(mean/s.d.)
48.8 (11.6) 46.1 (11.3) 40.1 (11.0) < 0.001
Quality of life-physical
mean/s.d.)
47.1 (10) 40.7 (10.8) 30.4 (8.4) < 0.001
IBS, irritable bowel syndrome; APD, abdominal pain/discomfort; SCL, Symptom Check list;
EPQ, Eysenck Personality Questionnaire.
* One way anova or chi-squared tests.
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as reduced QoL and ability to work and increased use of
health resources. These patients have a SC score above
16, which equals reporting severe intensity of ﬁve to six
different somatic symptoms (such as headache and low
back pain). We postulate that the comorbid somatic
symptoms and the psychological symptoms together
contribute to the reduced QoL and increased use of
health resources. These patients are likely to have a
sensitive mind in a sensitive body with bodily symptoms
associated with psychological distress. This somatization
trait may be acquired either by birth, by sensitization,
by learned illness behaviour or by underlying psychi-
atric disorders such as anxiety and depression.25, 26
Unfortunately, our cross-sectional study does not allow
determination of the nature or the direction of the
relationship between psychological symptoms and
somatic symptoms. Drawing such causal inferences
might be difﬁcult under any circumstance, since these
relations can be regarded as circular processes with
complex interactions in the brain-gut axis, more than
linear relationships.26 We suggest that it is more
important for doctors to identify the comorbid symp-
toms and help patients solve their current problems
than to establish ‘what came ﬁrst’. Furthermore, we
postulate that mind-based therapies such as hypnother-
apy, cognitive behaviour therapy (CBT) or tricyclic
antidepressants, could prove particularly efﬁcacious in
this subset of patients. The long-term effects of hypno-
therapy in IBS with regard to psychological distress, QoL
and use of health resources, as well as reduction of SC in
one study, lends promise to this approach.27, 28 A
current problem with hypnotherapy and CBT is their
limited availability, and that few GPs would consider
referral to such treatment.29, 30 Our ﬁndings suggest, in
contrast to what has been reported in referred
patients,31 that such intervention will be welcomed by
patients with IBS and excessive comorbidity, since the
majority related their abdominal complaints to stress
and psychological factors.
Patients with IBS and few or no other bodily symptoms
(low comorbidity) were characterized by apparently
normal psychological proﬁles, HRQoL, adverse life
events and ability to work. These individuals might be
more genuine IBS patients whose symptoms mainly
result from physiological disturbances in the gut, such
as visceral hypersensitivity, dysmotility or inﬂamma-
tion.32 Whether these patients will respond satisfactor-
ily to emerging drug therapies towards these
disturbances, are exciting possibilities which remain to
be studied. However, it is unclear how many of these
patients will need or want drug treatment for IBS given
their apparently normal HRQoL.
A ﬁnding of note is that the intensity of abdominal
pain/discomfort did not differ signiﬁcantly between the
groups, revealing the limitations of focusing purely on
GI symptoms in the clinical evaluation of patients with
IBS. We had expected fewer and less severe GI
symptoms in the low comorbidity group, based on
earlier reports and our ﬁndings of lighter overall
symptom load and better QoL.33 These patients might
have increased awareness towards abdominal symp-
toms, while the less specialized group with high
comorbidity might be somewhat distracted from their
abdominal symptoms by all the other symptoms and
problems they have.
Strengths and limitations
Strengths of our study, which should limit selection
bias, are that 92% of all attending patients were
screened for abdominal complaints, that the majority
of consecutive patients with IBS were included and that
those not included displayed apparently similar charac-
teristics to included patients. The use of validated
questionnaires for assessment of comorbid somatic and
psychological symptoms and QoL should make these
data reliable. The use of the SHC inventory allowed a
comparison of a wide range of symptoms between
patients with IBS and a large sample from a normal
population. The prospective design should make data on
the natural course of symptoms and HCS reliable.
However, methodological limitations are present. First,
these patients have IBS according to the Rome II
criteria, but not necessarily according to their GP, who
seldom use such criteria.34 This lack of diagnostic
agreement questions the applicability of our ﬁndings to
patients diagnosed with IBS by their GP. Secondly, the
excessive comorbidity reported by patients with IBS in
this study could potentially be features of the broader
medical population from which the patients were
selected. Thirdly, in addition to the above-mentioned
limitations with the dual aetiology hypothesis, we
cannot conﬁrm that merely counting comorbid somatic
symptoms will identify patients with different aetiologies
in IBS. The observed correlation between SC and
psychological distress emerged only when we included
the intensity of each comorbid symptom as an addi-
tional dimension. Palsson et al. reported a correlation at
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level with ours, by counting 26 frequent comorbid
symptoms in IBS, assessed in the Recent Physical
Symptoms Questionnaire (RPSQ).35 The SHC is prob-
ably less powerful than the RPSQ to measure SC in IBS,
which might explain why counting symptoms proved
unsuccessful in our study. On the contrary, comorbid
symptom intensity might be an additional dimension to
be included in the search for patients with predomin-
antly psychological aetiology in IBS.
CONCLUSIONS
Apart from being intriguing and strikingly frequent,
comorbid somatic symptoms might identify subgroups
of patients with IBS with different characteristics and
needs, as proposed in the dual aetiology hypothesis.
Structured assessment of SC, as part of a graded and
multicomponent approach, could provide caring doctors
with a necessary overview of their patients’ main
problems and reasons for suffering. Future research
should establish the aetiological and clinical implica-
tions of assessing comorbid symptoms and identifying
the proposed subgroups of patients, both with regard to
diagnosis and hopefully more effective treatment for this
large and heterogeneous group of patients.
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Abstract
Objective. To study the prevalence of irritable bowel syndrome (IBS) and its comorbidity in a Norwegian adult
population. Material and methods. In 2001, 11,078 inhabitants (aged 30/75 years) in Oppland County were invited to
take part in a public health survey. A total of 4622 subjects (42%) completed the questionnaires on symptoms of IBS (Rome
II criteria), comorbidity, health-care visits and medications. The impact of comorbidity on global health, working disability
and use of health-care resources in subjects with IBS was explored by stepwise logistic regression. Results. The population
prevalence of IBS was 388/4622 (8.4% (95% CI: 7.6/9.4%)) with a female predominance and an age-dependent decrease.
The proportion who had consulted for IBS ranged from 51% among 30-year-olds to 79% in 75-year-olds (p/0.05). IBS
was associated with musculoskeletal complaints (OR/2.4/3.4 for six different items), fibromyalgia (OR/3.6 [2.7/4.8]),
mood disorder (OR/3.3 (2.6/4.3)), reduced global health (OR/2.6 (2.1/3.2)), working disability (OR/1.6 (1.2/2.1)),
more frequent health-care visits and use of medications (OR 1.7/2.3). When controlling for comorbidity, reduced
global health (OR/1.5 (1.1/2.0)) and use of alternative health care (OR/1.7 (1.3/2.4)) remained associated with
IBS. Severity of abdominal pain/discomfort was a predictor of having to seek a consultation for IBS (OR/1.3
(1.2/1.5)). Conclusions. Symptoms of IBS were reported by 8% of Norwegian adults and had resulted in consultations
with physicians for the majority in the long run. Subjects with IBS in the community were characterized by frequent somatic
and psychiatric comorbidity. Their observed reduced health, working disability and increased use of health resources were
largely explained by comorbid symptoms and disorders.
Key Words: Epidemiology, ﬁbromyalgia, functional bowel disease, health resources, health survey, mood disorder,
Rome II criteria
Introduction
Irritable bowel syndrome (IBS) is a common func-
tional gastrointestinal disorder that is associated with
impaired quality of life and increased use of health
resources [1/3]. However, these associations are
possibly confounded by unmeasured somatic and
psychiatric disorders, which frequently co-occur
with IBS [4,5]. Most studies have assessed comorbid
disorders in those who consult physicians for IBS. It
is therefore unclear whether comorbidity is a feature
of IBS or of its consulters. Moreover, the comorbid-
ity of IBS has possible implications for aetiology,
diagnosis and treatment [4,6]. No studies have
formally addressed the prevalence of IBS in Norway.
Since IBS has no pathophysiological marker, its
definition and diagnosis depend entirely on clinical
features. The Rome II criteria are recommended for
epidemiological surveys of IBS [7,8].
The aim of this study was to measure the
prevalence of IBS in a Norwegian adult population
and to investigate the possible differences in char-
acteristics between 1) subjects with IBS and subjects
without IBS and 2) IBS consulters and IBS non-
consulters, with emphasis on somatic and psychiatric
comorbidity.
Material and methods
Study design and sample
This cross-sectional population-based survey was
conducted as part of the OPPHED (Oppland and
Hedmark) health study in 2001, performed by the
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National Health Screening Service (NHSS), now the
Norwegian Institute of Public Health. All men and
women in the selected age groups (born in 1970,
1960, 1955, 1940 and 1925) in the county of
Oppland (a mostly rural county with 183,000
inhabitants, of whom 53,000 live in two cities)
were invited by mail to participate. Of 11,078 invited
subjects, 4622 (42%) participated in this study and
completed the questionnaires, including an addi-
tional questionnaire regarding abdominal com-
plaints. The NHSS questionnaires were completed
in a bus located nearby the participants’ place of
living. The additional questionnaire was completed
at home and posted by mail to the NHSS. Non-
responders received two reminders. Responders
were more likely to be women than non-responders
(56% versus 51%, pB/0.001), more frequently born
in 1940 (23% versus 17%) and less frequently born
in 1970 (15% versus 22%) (pB/0.001). No other
characteristics were available for non-responders.
Measurement
OPPHED questionnaire. The questionnaire designed
by the NHSS has been used in several similar health
surveys in different regions of Norway and
is available at www.fhi.no/tema/helseundersokelse/
oslo/index.html. Questions were asked about socio-
demographic variables, including civil status, years
of education, working status, current global health
status (rated: poor, not very good, good, very good)
somatic and psychological comorbidity and use of
health resources. Somatic comorbidity was assessed
by six items on musculoskeletal complaints (MSCs)
within the past four weeks (neck/shoulder, arms/
hands, upper back, lower back, hip/legs/feet and
other locations) with the intensity of each complaint
rated as none, some, severe. A MSC score was
calculated by summarizing the scores of each item
(range 0/12). Current or earlier presence of fibro-
myalgia/chronic pain syndrome was also reported.
Symptoms of anxiety/depression were measured
with the Hopkins’ Symptom Check List-10 (SCL-
10) which consists of 10 questions with response
categories on a four-point ordinal scale ranging from
‘‘not at all’’ to ‘‘extremely’’. The average item score is
often used as a measure of psychological distress,
with a cut-off point of]/1.85 recommended as a
valid predictor of mood disorder [9]. The presence
of earlier or current mental problems, for which the
subject had applied for help, was noted.
Use of health resources was measured as the
number of health-care visits (0/1-3/ 4 or more)
within the last year to general practitioners (GPs),
psychiatrists/psychologists, other specialists and al-
ternative health-care providers, and the use of
medications (analgesics over the counter and anti-
depressants) during the past month (none/less than
weekly/weekly but not daily/daily).
Abdominal complaints questionnaire. The question-
naire included 26 items regarding specific bowel
symptoms based on the Rome II modular question-
naire which was translated into Norwegian by the
authors [7]. A 3-month time frame was used and
only the main criteria were used to diagnose IBS, as
recommended by the Rome II committee. The
additional supportive symptoms allowed a subdivi-
sion into diarrhoea-predominant IBS (D-IBS: two or
more diarrhoea symptoms and a maximum of one
symptom of constipation) constipation-predominant
IBS (C-IBS/two or more constipation symptoms
and a maximum of one symptom of diarrhoea) and
alternating IBS (A-IBS/all subjects with IBS not
qualifying for D-IBS or C-IBS). Abdominal pain
discomfort severity (mild/moderate/severe) and fre-
quency (average number of days per week: 0/1/2/3/
4/5//5) were recorded and multiplied to an in-
tensity score (range 0/12). The duration of abdom-
inal complaints (more or less than one year) and
earlier consultations with a physician for abdominal
complaints (lifelong, rated yes/no) were reported.
One question assessed whether subjects considered
that stress/psychological factors worsened the ab-
dominal complaints (stress-related symptoms).
Data analysis
The data were collected and entered into a data file
by the NHSS. Data were analysed by SPSS.
Prevalence estimates were calculated for the study
population and the target population (adults in
Oppland above 20 years of age). Corresponding
age- and gender-adjusted prevalence estimates were
computed by direct adjustment for age and gender
(5 age groups, 2 gender groups: total 10 groups)
using the direct adjustment method. These analyses
were done in order to adjust for the different
response rates between the groups. A logistic regres-
sion model was used to fit to the data, using birth
year and gender as predictors. Possible non-linearity
in birth year, as well as interaction, was checked and
found to be non-significant. The prevalence of IBS
in the target population was estimated by applying
the fitted logistic regression model to the total age
and gender-specific population of Oppland per
January 2001, available at Statistics Norway
(www.ssb.no).
Comparisons between different groups of subjects
were done by univariate and multivariate analyses.
The groups compared were subjects with IBS versus
AQ1
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subjects without IBS, IBS consulters versus IBS
non-consulters, IBS non-consulters versus subjects
without IBS and men with IBS versus women
with IBS. Univariate analyses were performed with
Pearson’s chi-square test, Student’s t-test or the
Wilcoxon-Mann-Whitney test. Multivariate analyses
were performed in stepwise logistic regression
models. The confounding effects of comorbidity
were examined by separate multivariate analyses
with global health, working disability, use of health
care and medications as dependent variables. IBS,
comorbid symptoms (MSC score, fibromyalgia,
mood disorder, earlier or current mental problems),
age and gender were independent variables in the
separate analyses. In addition, stepwise logistic
regression models were used to identify predictors
of having consulted for IBS (IBS consulters versus
IBS non-consulters) and to control for confounding
effects of consultation behaviour on characteristics
associated with IBS (IBS non-consulters versus
subjects without IBS). In these models, variables
with p-valuesB/0.20 in the univariate analysis were
entered.
Statistics are reported as estimates with odds
ratios (ORs) and 95% confidence intervals (CIs)
for ordinal variables, and as p-values for continuous
variables, with the level of statistical significance
specified at 0.05.
Ethics
The survey was performed in accordance with the
Declaration of Helsinki, and approved by the Re-
gional Committee of Research Ethics and the Data
Inspectorate, Oslo.
Results
Prevalence of IBS
Of the 4622 subjects included in the study, 388
reported IBS according to the Rome II criteria,
yielding an overall unadjusted prevalence of IBS for
all the five birth-year cohorts of 8.4% (95% CI: 7.6/
9.2%). Figure 1 shows the observed age and gender-
specific prevalence of IBS, and prevalence estimates
derived from the fitted logistic regression model.
The prevalence of IBS in the target population was
estimated to 8.1% for all, 6.3% for men and 9.8%
for women. Fifty-four subjects (14%) reported IBS
symptoms of less than one year’s duration.
Characteristics of subjects with IBS
The characteristics of subjects with IBS, compared
with those of 4234 subjects without IBS are pre-
sented in Table I. In the 388 subjects with IBS, the
intensity of abdominal pain/discomfort was mild in
49%, moderate in 47% and severe in 4%, while 9%
reported the presence of abdominal pain/discomfort
for more than five days per week. The most common
additional symptoms were abdominal bloating
(96%), straining (80%), incomplete evacuation
(76%) and urgency (61%). D-IBS was reported by
23%, C-IBS by 24% and A-IBS by 53%.
In the 388 subjects with IBS, statistically signifi-
cant gender differences were observed. In men and
women, mean intensity levels of abdominal pain/
discomfort were 3.6 and 3.0, respectively (p/0.01),
mean intensity levels of musculoskeletal complaints
were 3.4 and 4.0, respectively (p/0.05) and mean
psychological distress levels were 1.4 and 1.5,
respectively (p/0.03). We found that 37% of men
and 16% of women had D-IBS, and 13% of men and
29% of women had C-IBS (pB/0.001). Women
reported fibromyalgia more frequently than men
(26% versus 9%, pB/0.001).
The univariate analysis showed that IBS was
significantly associated with reduced global health,
working disability, use of health care and medica-
tions (Table I). When controlling for comorbidity,
age and gender in the multivariate analysis,
IBS remained statistically significantly associated
with reduced global health (OR/1.5 (1.1/2.0))
and visits to alternative health care (OR/1.7
(1.3/2.4)), but not with working disability, visits to
GPs, visits to psychiatrists or other specialists, or use
of analgesics or antidepressants. Fibromyalgia
(OR/2.5) and mental problems (OR/1.9) were
more strongly associated with reduced global health
than IBS in the multivariate analysis. Accordingly,
the association between IBS and reduced global
health was reduced in the multivariate analysis
(OR/1.5) when compared with the univariate
analysis (OR/2.6, Table I). Use of alternative
Figure 1. Observed prevalence of irritable bowel syndrome (IBS),
and estimated mean prevalence with 95% conﬁdence interval
from the ﬁtted logistic regression model.
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health care was most strongly associated with IBS in
the multivariate analysis, with mental problems
(OR/1.4) and MSC score (OR/1.2) as other
significant predictors.
Characteristics of IBS consulters and IBS non-consulters
In all, 235 subjects with IBS (61%) had sought
consultations for abdominal complaints (IBS con-
sulters). The proportion that had consulted in-
creased with age, from 51% among 30-year-olds to
79% in 75-year-olds (p/0.05, chi-square for trend).
Sixty-eight (44%) of the 153 IBS non-consulters
wished to consult a physician for their abdominal
complaints, leaving 82 (21%) of 388 subjects with
IBS who had never consulted nor wished to consult
for IBS. The results of a comparison between IBS
consulters and IBS non-consulters are reported in
Table II. In the multivariate analysis of predictors of
having consulted for IBS (IBS consulters), the
intensity of abdominal pain/discomfort (OR/1.3
(1.2/1.5)) remained significant.
We also made a comparison of IBS non-consulters
versus subjects without IBS for all variables shown in
Table I. This analysis was performed to determine
whether the observed characteristics in subjects with
IBS could be confounded by consultation behaviour.
In the univariate analysis, the following variables
remained associated with IBS (all p-valuesB/0.001):
Female gender (OR/1.8), reduced global health
(OR/1.7), somatic comorbidity (OR 1.9/2.6 for
six items of MSC and OR/2.2 for fibromyalgia),
psychiatric comorbidity (OR/1.9 for mental pro-
blems and OR/3.2 for mood disorder) visits to
psychiatrists (OR/3.2) and use of analgesics (OR/
2.2). In the multivariate analysis, female gender,
reduced global health, somatic and psychiatric
comorbidity and visits to psychiatrists remained
associated with IBS (all p-valuesB/0.001).
Discussion
Main findings
Our study clearly demonstrates that comorbid
symptoms and disorders are common features in
adults with IBS in the general population of Norway.
This finding is important because studies have
mainly assessed comorbidity in those who seek
health care for IBS [4,10]. In concert with these
studies, the odds for reporting a variety of MSCs,
fibromyalgia, mental problems or current mood
disorders were two to three times higher in subjects
with IBS than in subjects without IBS. Importantly,
somatic and psychiatric comorbidity remained asso-
Table I. Characteristics of subjects with and without IBS (non-IBS). Results are given as whole percentages or mean values with standard
deviations.
Variable IBS n/388 Non-IBS n/4234
Statistics OR (95% CI)
or p -values
Female gender 68 55 1.7 (1.4/2.1)
Marital status / separated 4 2 2.2 (1.3/3.9)
Years of education (mean/SD) 12 (3.5) 12 (3.5) p/0.49
Disability pension 19 13 1.6 (1.2/2.1)
Global health poor or not very good 44 23 2.6 (2.1/3.2)
Comorbidity
Pain in shoulder 76 53 2.7 (2.1/3.5)
Pain arms/hands 59 36 2.6 (2.1/3.3)
Pain upper back 48 23 3.2 (2.5/4.0)
Pain lower back 68 45 2.6 (2.1/3.4)
Pain hips/legs/feet 65 43 2.4 (1.9/3.0)
Pain other locations 22 8 3.4 (2.5/4.7)
Musc. skel. pain intensity score (mean/SD) 3.8 (2.8) 2.4 (2.3) pB/0.001
Fibromyalgia/chronic pain syndrome 20 7 3.6 (2.7/4.8)
Earlier or present mental problems 27 12 2.6 (2.0/3.4)
Mood disorder (SCL-10) 25 9 3.3 (2.6/4.3)
Health-care visits last year
/4 GP visits 36 22 2.0 (1.6/2.5)
Psychologist/psychiatrist 8 3 2.7 (1.7/4.1)
Other specialist 39 28 1.7 (1.3/2.1)
Alternative health care 21 10 2.3 (1.7/3.1)
Use of drugs in the past month (/weekly)
Analgesics over the counter 22 11 2.3 (1.8/3.1)
Antidepressants 10 5 2.3 (1.6/3.3)
Abbreviations: IBD/irritable bowel syndrome; SCL/symptom check list; GP/general practitioner.
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ciated with IBS after controlling for consultation
behaviour (IBS non-consulters versus subjects with-
out IBS). With regard to psychiatric comorbidity,
the increased prevalence of mood disorders (25%) in
both IBS consulters and non-consulters contrasts
with the prevailing opinion that non-consulters with
IBS display psychological profiles similar to those in
the general population [11,12]. Our findings are
supported by two other studies [1,13] and demon-
strate the interplay between psychology and biology
also in those who do not consult for their IBS
symptoms.
The hypothesis that comorbid symptoms con-
founded the observed reduced global health status,
working disability and increased health-care seeking
and use of analgesics was largely confirmed. In our
previous study of IBS in general practice, patients
with excessive somatic comorbidity reported fre-
quent psychiatric problems (mood disorder in
63%), markedly reduced quality of life and increased
use of health resources, when compared with those
with few or no comorbid symptoms [10]. Taken
together, our findings suggest that comorbid symp-
toms and disorders need to be considered when
measuring the impact of IBS on people’s lives and
costs for the community. Furthermore, the comor-
bidity of IBS might indicate predominantly different
aetiologies and have possible implications for the
diagnosis and treatment of IBS [4,6]. Subsets of
patients with IBS and excessive somatic comorbidity
might have a predominantly psychological aetiology
and benefit from psychological interventions, such as
hypnotherapy or tricyclic antidepressants [14].
Those without comorbidity might have a predomi-
nantly biological aetiology and could respond well to
novel drug therapies for IBS. Our findings are
perhaps of particular relevance these days when
drugs targeted towards specific symptoms of IBS
are being marketed.
With regard to the prevalence of IBS, 8% reported
IBS according to the Rome II criteria with a female
predominance and an age-dependent decrease, in
line with other surveys of Rome II IBS in Europe
(prevalence 9.6%), Canada (prevalence 12.1%) and
Australia (prevalence 6.9%) [1,8,15]. In Sweden,
7% of men and 13% of women had IBS, but it is
unclear which criteria were used [11]. In Spain, a
2.9% prevalence of Rome II IBS has been reported
[16]. Although the Rome II criteria represent the
strictest criteria, they show satisfactory agreement
with the earlier Rome criteria [8,17]. It remains to be
determined whether the observed differences in
Rome II prevalence estimates reflect geographical
variations as suggested by the European study, or
rather reflect methodological differences such as
selection procedures, cultural interpretations or
differences in translation and wording [1]. Impor-
tantly, the role of diagnostic criteria in clinical
practice is unclear since they have not been formally
validated in relevant clinical settings.
Some other characteristics of IBS should be noted.
Few subjects (7%) reported severe abdominal pain/
Table II. Characteristics of IBS consulters and IBS non-consulters. Results are given as whole percentages or mean values with standard
deviations (SD).
Variable IBS consulters n/235 IBS non-consulters n/152
Statistics OR (95% CI)
or p -values
Female gender 66 69 1.1 (0.7/1.8)
Disability pension (75-year-olds excluded) 22 15 1.6 (0.9/2.9)
Global health poor or not very good 51 34 2.0 (1.3/3.1)
Gastrointestinal symptoms
Abd. pain/discomfort score (mean/SD) 3.7 (2.7) 2.5 (1.6) pB/0.001
Stress-related symptoms 63 73 0.6 (0.4/1.0)
Comorbidity
Musc. skel. Pain intensity score (mean/SD) 4.1 (2.8) 3.4 (2.5) p/0.02
Fibromyalgia/chronic pain syndrome 25 14 2.0 (1.1/3.5)
Earlier or present mental problems 31 22 1.6 (1.0/2.6)
Mood disorder (SCL-10/1.85) 25 25 1.0 (0.6/1.6)
Health-care visits last year
/4 GP visits 42 27 2.0 (1.3/3.1)
Psychologist/psychiatrist 7 10 0.7 (0.3/1.6)
Other specialist 46 29 2.1 (1.3/3.3)
Alternative health care 27 13 2.5 (1.4/4.6)
Use of drugs in the past month (/weekly)
Analgesics (over the counter) 23 21 1.1 (0.7/1.8)
Antidepressants 12 7 1.7 (0.8/3.5)
Abbreviations: IBD/irritable bowel syndrome; SCL/symptom check list; GP/general practitioner.
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discomfort and 86% reported having symptoms of
IBS for more than one year, in line with what is
reported by patients with IBS in general practice
[10]. Current knowledge about IBS, including the
efficacy of treatment, is mostly based on studies of
small subsets of referred patients [18]. We confirm
that the severity of symptoms is a major predictor of
health-care seeking in IBS [19]. A pertinent ques-
tion, given the apparent mildness of IBS and the
impact of comorbidity observed in our studies, is
whether the majority of adults with IBS in the
community and in general practice will need specific
treatment for symptoms of IBS. The male predomi-
nance of D-IBS and female predominance of C-IBS
was unexpected. More than half the subjects with
IBS had consulted a physician for their abdominal
complaints, with an age-dependent increase of up to
79% in the 75-year-olds. One possible explanation
for the observed high proportion of IBS consulters,
similar to that reported from Australia but higher
than in other Western countries, is the public health-
care system in Norway with its high accessibility and
low costs for the patient [1,20].
Strengths and limitations
The strengths of our survey are the population-based
design, the substantial number of subjects with IBS
identified and the use of well-defined criteria for
IBS. The main limitation of our survey is the modest
response rate (42%). This might introduce selection
bias and reduce the external validity of our findings,
particularly with regard to prevalence estimates
which are more sensitive for selection bias than
measures of association. However, self-selection
according to socio-demographic variables had little
impact on prevalence estimates and measures of
association in a study of non-responders in the Oslo
Health Study. This NHSS survey had an identical
design to our study and was conducted in 2001 with
a 46% response rate [21]. Another limitation is that
we have no information regarding diagnoses of
abdominal complaints. In the US householder
survey, 3% of subjects with IBS according to the
Rome criteria reported the presence of organic
disease, which suggests a slight overestimate of
prevalence in our study [22]. Furthermore, our
translation of the Rome II criteria was not formally
validated, which might have introduced information
bias because of differences in wording. The Rome II
questionnaires developed for research purposes have
not been formally validated and were impossible to
apply in our survey. Assessment of IBS symptoms
within the recommended three-month time frame
probably reduces recall bias. However, some might
have had symptoms of IBS for more than three
months during the past year, but not within the past
three months. Since these patients would qualify for
a diagnosis of IBS according to the Rome II criteria,
we might have underestimated the true prevalence of
IBS. With regard to characteristics of subjects with
IBS, measurement of other commonly occurring
comorbid disorders, worry about cancer/serious
disease (as a predictor of consultations for IBS),
quality of life and use of health resources specifically
related to IBS would have strengthened our results.
Finally, confounding is an inherent problem with
descriptive studies that cannot fully be controlled by
entering comorbidity, age and gender in a logistic
regression model. Although other unmeasured fac-
tors might contribute, it seems plausible that co-
morbid symptoms and disorders play a main part in
explaining the observed reduced global health and
increased use of health resources.
Conclusion and implications for future research
In a highly prevalent chronic disorder reported by
8% of adults in the community which leads to
consultations with physicians for the majority in
the long run, optimal diagnosis and treatment
should be of high priority. We provide further
evidence to show that psychiatric and somatic
comorbidities are common features in IBS and not
just features of its consulters. Moreover, the comor-
bidity explained a substantial part of the reduced
global health and increased use of health resources
associated with IBS. The comorbidity of IBS might
also have implications for aetiology, diagnosis and
treatment. The role of diagnostic criteria in clinical
practice needs to be determined since our knowledge
of IBS largely depends on studies employing these
criteria.
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There once was a fellow from Sparta
A really magnificent farter
On the strength of one bean,
He farted "God save the Queen"
And Beethoven`s "Moonlight Sonata."
- Anonymous - 
